<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:media="http://search.yahoo.com/mrss/"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:company="http:/purl.org/rss/1.0/modules/company" xmlns:fool="https://fool.com/rss/extensions"     >

    <channel>
        <title>Ramsay Health Care (ASX:RHC) Share Price News | The Motley Fool Australia</title>
        <atom:link href="https://www.fool.com.au/tickers/asx-rhc/feed/" rel="self" type="application/rss+xml" />
        <link>https://www.fool.com.au/tickers/asx-rhc/</link>
        <description>Since 1993, millions of investors have trusted The Motley Fool for simple, down-to-earth investing research.</description>
        <lastBuildDate>Fri, 20 Nov 2026 13:30:00 +0000</lastBuildDate>
        <language>en-AU</language>
                <sy:updatePeriod>hourly</sy:updatePeriod>
                <sy:updateFrequency>1</sy:updateFrequency>
        <generator>https://wordpress.org/?v=7.0.9</generator>

<image>
	<url>https://www.fool.com.au/wp-content/uploads/2020/06/cropped-cap-icon-freesite-96x96.png</url>
	<title>Ramsay Health Care (ASX:RHC) Share Price News | The Motley Fool Australia</title>
	<link>https://www.fool.com.au/tickers/asx-rhc/</link>
	<width>32</width>
	<height>32</height>
</image> 
<atom:link rel="hub" href="https://pubsubhubbub.appspot.com"/>
<atom:link rel="hub" href="https://pubsubhubbub.superfeedr.com"/>
<atom:link rel="hub" href="https://websubhub.com/hub"/>
<atom:link rel="self" href="https://www.fool.com.au/tickers/asx-rhc/feed/"/>
            <item>
                                <title>Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares</title>
                <link>https://www.fool.com.au/2026/11/20/buy-hold-sell-hub24-reece-ramsay-healthcare-shares/</link>
                                <pubDate>Fri, 20 Nov 2026 02:22:35 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1891233</guid>
                                    <description><![CDATA[<p>Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator. </p>
<p>The post <a href="https://www.fool.com.au/2026/11/20/buy-hold-sell-hub24-reece-ramsay-healthcare-shares/">Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) shares are down 1.5% to 8,597.8 points on Friday.  </p>



<p class="wp-block-paragraph">A heavy fall for technology, down 5.8%, and a 1.9% drop for the materials and miners sector is dragging the bourse down today.</p>



<p class="wp-block-paragraph">Meanwhile, here are some new ratings from the experts (courtesy <em><a href="https://thebull.com.au/18-share-tips/18-share-tips-16th-november-2026/" target="_blank" rel="noreferrer noopener">The Bull</a></em>).&nbsp;&nbsp;</p>



<h2 id="h-hub24-ltd-asx-hub" class="wp-block-heading">Hub24 Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-hub/">ASX: HUB</a>)</h2>



<p class="wp-block-paragraph">The Hub24 share price is $70.80, down 3% today and down 32% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Hub24 is a financial services platform that allows advisors and institutions to manage their clients' investments and superannuation.</p>



<p class="wp-block-paragraph">Steven Springford from Catapult Wealth noted a 15% year-over-year increase in funds under administration in the September quarter.</p>



<p class="wp-block-paragraph">However, cash inflows fell 23% over the quarter. </p>



<p class="wp-block-paragraph">Springford has a buy rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/financial-shares/">financial share</a>.&nbsp;</p>



<p class="wp-block-paragraph">He said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">I expect platform net inflows to recover after falling 23 per cent in the quarter to $4 billion. </p>



<p class="wp-block-paragraph">I believe HUB offers value given the shares were priced at $115.44 on November 11, 2025. </p>



<p class="wp-block-paragraph">The company increased total fully franked <a href="https://www.fool.com.au/definitions/dividend/">dividends</a> in full year 2026 by 39 per cent compared to the prior corresponding period.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Hub24 Price" data-ticker="ASX:HUB" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</strong></h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price is $53.79, down 1.1% today and up 69% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Ramsay is one of Australia's largest private hospital network operators. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">Springford has a hold rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a>. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">He noted a solid set of results for FY26, including a near 23% year-over-year uplift in underlying group net profit after tax to $364.1 million. </p>



<p class="wp-block-paragraph">Investors were rewarded with a 48.5-cent fully-franked final dividend for the second half, up 21.3%.</p>



<p class="wp-block-paragraph">Springford said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Management expects further revenue growth and margin improvement in full year 2027. </p>



<p class="wp-block-paragraph">The operating recovery is encouraging, but the valuation already assumes continuing improvement. </p>



<p class="wp-block-paragraph">The proposed Ramsay Sante separation and shareholder vote are key upcoming catalysts for price movement, so investors should gauge the outcome of the result.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Ramsay Health Care Price" data-ticker="ASX:RHC" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<h2 id="h-reece-ltd-asx-reh" class="wp-block-heading"><strong>Reece Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-reh/">ASX: REH</a>)</strong></h2>



<p class="wp-block-paragraph">The Reece share price is $18.31, down 1.9% today and up 70% over 12 months.  </p>



<p class="wp-block-paragraph">Reece is a plumbing supplies company that operates in Australia, New Zealand, and the US. </p>



<p class="wp-block-paragraph">Andrew Wielandt from DP Wealth Advisory said Reece shares are rallying this month following the company's <a href="https://www.fool.com.au/tickers/asx-reh/announcements/2026-10-30/3a705448/trading-update-q1-fy27/">1Q FY27 trading update</a>.</p>



<p class="wp-block-paragraph">Reece reported sales revenue of $2.510 billion, up 4.3% on the prior corresponding period. </p>



<p class="wp-block-paragraph">Wielandt has a sell rating on this ASX 200 industrial share.&nbsp;</p>



<p class="wp-block-paragraph">He said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Australia and New Zealand produced a strong first quarter. However, the US remained soft in response to a subdued new residential construction market impacting the business. </p>



<p class="wp-block-paragraph">The company expects a challenging environment to continue in the US. </p>



<p class="wp-block-paragraph">We would be inclined to cash in some gains until the US residential construction market shows signs of a sustained recovery.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Reece Price" data-ticker="ASX:REH" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/11/20/buy-hold-sell-hub24-reece-ramsay-healthcare-shares/">Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>I hunted the ASX for shares that could end 2026 on a high: These 3 stood out</title>
                <link>https://www.fool.com.au/2026/11/06/i-hunted-the-asx-for-shares-that-could-end-2026-on-a-high-these-3-stood-out/</link>
                                <pubDate>Thu, 05 Nov 2026 22:17:15 +0000</pubDate>
                <dc:creator><![CDATA[Samantha Menzies]]></dc:creator>
                		<category><![CDATA[Opinions]]></category>
		<category><![CDATA[editor's choice]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1887978</guid>
                                    <description><![CDATA[<p>Find out why these ASX shares caught my eye.</p>
<p>The post <a href="https://www.fool.com.au/2026/11/06/i-hunted-the-asx-for-shares-that-could-end-2026-on-a-high-these-3-stood-out/">I hunted the ASX for shares that could end 2026 on a high: These 3 stood out</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">It's been an interesting year for ASX shares so far. <a href="https://www.fool.com.au/investing-education/inflation/">Inflation</a> woes, cost-of-living fears, cash rate hikes, a slumping property market, and geopolitical volatility have sent investors into a panic and share market indexes have swung between peaks and troughs.</p>



<p class="wp-block-paragraph">But now, there's only around eight weeks left of the 2026 calendar year. And with the remaining few weeks now in sight, it's only natural that I have my sights on which ASX shares are going to finish the year strongly.   </p>



<p class="wp-block-paragraph">So I decided to hunt around for ASX shares which have quietly remained strong or rebounded. And pinpoint those with potential to end on a high in 2026.  </p>



<p class="wp-block-paragraph">And these three caught my attention.  </p>



<h2 id="h-megaport-ltd-asx-mp1" class="wp-block-heading"><strong>Megaport Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-mp1/">ASX: MP1</a>)</strong></h2>



<p class="wp-block-paragraph">Megaport shares suffered a sell-off through the first quarter of 2026, before reaching a three-year low of just $6.48 in early-April. </p>



<p class="wp-block-paragraph">The decline was due to a combination of company and market-wide headwinds. These include a sector-wide rotation away from technology shares, AI fears, a disappointing first-half result, revised earnings guidance, and investor concerns about mounting acquisition costs.  </p>



<p class="wp-block-paragraph">But since hitting that multi-year low, Megaport's headwinds cooled and its shares stormed back into life. A surge in investor confidence in technology stocks, a strong FY26 earnings result, and several new contract wins has seen a huge 173% share price rebound to the time of writing. </p>



<p class="wp-block-paragraph">In August, Megaport reported an impressive FY26 result. Highlights include a 37% increase in revenue, a 24% increase in <a href="https://www.fool.com.au/definitions/ebitda/">EBITDA</a>, and a 62% hike in group annual recurring revenue. The results came in at the high end of <a href="https://www.fool.com.au/definitions/company-guidance/">guidance</a>.</p>



<p class="wp-block-paragraph">Megaport has also confirmed several new contract wins between late April and late September, including $1 billion of <a href="https://www.fool.com.au/investing-education/ai-shares-asx/">AI</a> deals in late September. </p>



<p class="wp-block-paragraph">The NaaS (Network-as-a-Service) provider said it has signed three AI infrastructure contracts through Megaport's Latitude.sh business. These are worth roughly $978.6 million in total.&nbsp;</p>



<p class="wp-block-paragraph">The new agreements have brought Megaport's combined total contract value for strategic contracts announced since April 2026 to $2.3 billion. </p>



<p class="wp-block-paragraph">But it wasn't only Megaport's share price resurgence which caught my attention. </p>



<p class="wp-block-paragraph">There is an upcoming catalyst for Megaport's shares before the end of the year.</p>



<p class="wp-block-paragraph">The company is scheduled to hold its AGM on 26th of November. The results of which I think could propel the share price higher.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">The latest share price rally is good news, but the market wants more concrete proof that the company is able to make good on its promise for operational excellence. </p>



<p class="wp-block-paragraph">Investors will want to know if Megaport can show a clear demonstration of how it plans to translate its $2.3 billion of contract wins into an annual recurring revenue. </p>



<p class="wp-block-paragraph">If Megaport is able to reassure investors, at its AGM, of a clear plan for a return to profitability, and is able to give a trading update which confirms its upgraded FY27 revenue guidance, I think we could see another strong share price rally, ending 2026 on a high. </p>





<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) </strong></h2>



<p class="wp-block-paragraph"><a href="https://www.fool.com.au/investing-education/healthcare-shares/">ASX healthcare</a> shares have suffered from intense volatility so far in 2026, driven by unstable inflation and a general investor rotation away from the healthcare sector.    </p>



<p class="wp-block-paragraph">But interestingly, Ramsay shares have bucked the trend and travelled in the other direction. </p>



<p class="wp-block-paragraph">Ramsay shares climbed higher through the first half of 2026, before jumping 17% in late-August after the company posted its FY26 results. </p>



<p class="wp-block-paragraph">The company reported a 22.9% increase in its underlying net profit after tax (NPAT) and an 11.8% increase in its underlying EBIT. Revenue also climbed 4.2%.&nbsp;</p>



<p class="wp-block-paragraph">Shareholders also received a <a href="https://www.fool.com.au/definitions/dividend/">dividend</a> increase, up 13.8% to 91 cents per share for the full year FY26.</p>



<p class="wp-block-paragraph">Since the results announcement, the shares have been pretty stable and hovering around the $55-mark. In fact, the ASX shares closed at a 52-week high of $56.23 on Thursday afternoon.  </p>



<p class="wp-block-paragraph">What sets Ramsay apart from the rest of the share market isn't just its share price gains this year, but also its ongoing growth plans.</p>



<p class="wp-block-paragraph">Looking ahead, Ramsay expects to report EBIT growth and further margin improvement in FY27, with ongoing focus on cost management, activity growth, and capital discipline.  </p>



<p class="wp-block-paragraph">The company is also moving ahead with plans to separate its 52.79% stake in <strong>Ramsay Santé</strong>, which owns hospitals across Europe.</p>



<p class="wp-block-paragraph">I think the demerger will be the main catalyst for short-term share price growth.&nbsp;</p>



<p class="wp-block-paragraph">Shareholders are voting on the demerger at its AGM on the 24th of November. If they vote "yes", then as of the 27th of November, the demerger will be legally binding.  </p>



<p class="wp-block-paragraph">The company's European Ramsay Santé business has been underperforming since late-2023, persistently dragging down group earnings.   </p>



<p class="wp-block-paragraph">And I expect that we'll get more insight about what it means for immediate shareholder value and near-term tailwinds at its AGM and shareholder vote on the 24th of November.   </p>



<p class="wp-block-paragraph">Investors are also eagerly waiting to hear how Ramsay's plan to simplify the business to focus on UK and Australian hospitals could drive more long-term growth. I expect that we could see a strong uptick in investor interest in Ramsay shares in late-November to fresh annual highs.  </p>



<h2 id="h-bega-cheese-ltd-asx-bga" class="wp-block-heading"><strong>Bega Cheese Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-bga/">ASX: BGA</a>)</strong> </h2>



<p class="wp-block-paragraph">Bega Cheese shares have been relatively buoyant throughout 2026 so far. They've mostly fluctuated between $5.50 and $6, with the exception of a dip in May.  </p>



<p class="wp-block-paragraph">There wasn't any price-sensitive news out of the company at the time to explain the dip. It was most likely due to broad geopolitical uncertainty and high interest rates, which pushed investors toward <a href="https://www.fool.com.au/investing-education/defensive-shares/">defensive assets</a>. </p>



<p class="wp-block-paragraph">The company has undergone a huge cost-cutting exercise this year. Bega Cheese has reduced its manufacturing footprint to 15, from 22 sites. It has also reduced its headcount by roughly 800 to 900 roles. </p>



<p class="wp-block-paragraph">Bega Cheese also impressed the market with a huge financial turnaround this year. The company reported statutory net profit after tax of $54.8 million for FY26. This was up from a net loss of $8.5 million in FY25. </p>



<p class="wp-block-paragraph">Revenue also rose 6.7% to $3.77 billion, and normalised EBITDA increased 12% to $225.6 million.</p>



<p class="wp-block-paragraph">The huge swing from a loss to strong growth caught my attention. And I took a closer look to see if that growth is sustainable going forward. </p>



<p class="wp-block-paragraph">Bega Cheese said its branded segment saw solid growth from strong sales of yoghurt, milk beverages, and international revenues. Higher demand for protein and health-focused products, plus cost savings from existing primary peanut processing, helped boost results. </p>



<p class="wp-block-paragraph">Going forward, the company said it is now targeting more than $310 million in normalised EBITDA by FY31. Investment in marketing and automation is expected to drive continued growth in core dairy and better-for-you products.</p>



<p class="wp-block-paragraph">Management has provided normalised EBITDA guidance in the range of $240 million to $245 million for FY27. This is supported by ongoing demand for protein and strong international sales, particularly in Southeast Asia.</p>



<p class="wp-block-paragraph">What jumps out to me about Bega shares is that the company has a reputation for issuing achievable guidance, rather than overpromising.    </p>



<p class="wp-block-paragraph">Take the latest results announcement, for example, which came in way ahead of expectations.&nbsp;</p>



<p class="wp-block-paragraph">This makes me question whether Bega Cheese's revenue and net profit could climb a lot higher, and quicker, than we expect.</p>



<p class="wp-block-paragraph">At the time of writing, the ASX shares are around 3% below the year-to-date high. I think the financial turnaround, cost-cutting measures, and streamlined operations could continue to propel the shares higher over the next eight weeks, ending the year on a high. </p>
<p>The post <a href="https://www.fool.com.au/2026/11/06/i-hunted-the-asx-for-shares-that-could-end-2026-on-a-high-these-3-stood-out/">I hunted the ASX for shares that could end 2026 on a high: These 3 stood out</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Buy, hold, sell: Liontown, Ramsay Healthcare, ANZ shares</title>
                <link>https://www.fool.com.au/2026/11/03/buy-hold-sell-liontown-ramsay-healthcare-anz-shares/</link>
                                <pubDate>Tue, 03 Nov 2026 02:15:53 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1887208</guid>
                                    <description><![CDATA[<p>Let's take a look at some new ratings on three ASX 200 shares.</p>
<p>The post <a href="https://www.fool.com.au/2026/11/03/buy-hold-sell-liontown-ramsay-healthcare-anz-shares/">Buy, hold, sell: Liontown, Ramsay Healthcare, ANZ shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) shares are up 0.3% to 8,880.7 points on Tuesday.</p>



<p class="wp-block-paragraph">Let's take a look at some new ratings on three ASX 200 shares. </p>



<h2 id="h-liontown-ltd-asx-ltr" class="wp-block-heading"><strong><strong>Liontown Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-ltr/">ASX: LTR</a>)</strong></strong></h2>



<p class="wp-block-paragraph">The Liontown share price is 61 cents, up 0.8% today and down 48% over 12 months.  </p>



<p class="wp-block-paragraph">Bell Potter analyst Stuart Howe says Liontown shares are the broker's preferred lithium exposure. </p>



<p class="wp-block-paragraph">Howe has a buy rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/lithium-shares/">lithium share</a> given the company's plans to expand its Kathleen Valley operations.&nbsp;</p>



<p class="wp-block-paragraph">Howe said:  </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We expect a value re-rate as the Kathleen Valley ramp-up and expansion are progressively derisked over the forecast period.</p>



<p class="wp-block-paragraph">The company is in a strong net cash position to support the incremental and low capital intensity Kathleen Valley expansion. </p>
</blockquote>



<p class="wp-block-paragraph">The analyst noted that lithium prices have fallen in recent times. </p>



<p class="wp-block-paragraph">As we've reported, this is due to <a href="https://www.fool.com.au/2026/10/29/asx-lithium-shares-take-a-hit-amid-20-fall-in-lithium-price/">changing short-term supply/demand dynamics</a>. </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Despite recent lithium price weakness, we remain positive on a medium to longer term outlook with market supply likely to<br>disappoint against strong demand themes.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Liontown Price" data-ticker="ASX:LTR" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<blockquote class="wp-block-quote"></blockquote>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</strong></strong></h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price is $55.10, down 1.2% today and up 74% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Ramsay Health Care is one of Australia's largest private hospital networks. </p>



<p class="wp-block-paragraph">The Ramsay Health Care share price has been in a gradual process of recovery over the past 12 months. </p>



<p class="wp-block-paragraph">When the <a href="https://www.fool.com.au/2026/09/10/asx-healthcare-shares-are-39-higher-since-june-are-you-missing-out/">whole healthcare sector pivoted in June</a> after a prolonged slump, Ramsay shares powered up further. </p>



<p class="wp-block-paragraph">Remo Greco from Sanlam Private Wealth has a hold rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a> for now. </p>



<p class="wp-block-paragraph">Greco said (courtesy <em><a href="https://thebull.com.au/18-share-tips/18-share-tips-2nd-november-2026/" target="_blank" rel="noreferrer noopener">The Bull</a></em>):  </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">The recent full year 2026 results were better than expected.</p>



<p class="wp-block-paragraph">The proposed de-merger of Ramsay Sante in Europe will enable the management team to focus even more on its Australian operations. </p>



<p class="wp-block-paragraph">Management expects further revenue growth and margin improvement in full year 2027. </p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Ramsay Health Care Price" data-ticker="ASX:RHC" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<h2 id="h-anz-group-holdings-ltd-asx-anz" class="wp-block-heading"><strong><strong>ANZ Group Holdings Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-anz/">ASX: ANZ</a>)</strong></strong></h2>



<p class="wp-block-paragraph">The ANZ share price is $40.06, down 1.2% today and up 8% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">It's reporting season for three of the four major ASX 200 <a href="https://www.fool.com.au/investing-education/bank-shares/">bank shares</a>.&nbsp; </p>



<p class="wp-block-paragraph"><strong>Westpac Banking Corp </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wbc/">ASX: WBC</a>) went first yesterday, <a href="https://www.fool.com.au/2026/11/02/westpac-fy26-results-would-i-buy-the-banks-shares/">announcing</a> a 1% fall in statutory net profit to $6.8 billion for FY26.</p>



<p class="wp-block-paragraph">Both ANZ and <strong>National Australia Bank Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nab/">ASX: NAB</a>) will report their FY26 results on 9 November.</p>



<p class="wp-block-paragraph">Investors are watching for any signs of weaker residential lending growth in light of the housing market downturn.</p>



<p class="wp-block-paragraph">Elio D'Amato from EnviroInvest has a sell rating on ANZ shares because the bank is considering financing a gas pipeline. </p>



<p class="wp-block-paragraph">The <a href="https://www.apa.com.au/news/transmission-industry-insights/beetaloo-the-pipeline-to-the-territory-s-future">proposed gas pipeline in Beetaloo</a> belongs to <strong>APA Group </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-apa/">ASX: APA</a>). </p>



<p class="wp-block-paragraph">D'Amato said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">While no project funding commitment has been verified at this time, potential support for infrastructure enabling further fracking exposes the bank to climate and reputational risks, in our view. </p>



<p class="wp-block-paragraph">The environmental concern includes emissions from gas production and combustion. </p>



<p class="wp-block-paragraph">For investors seeking stronger restrictions on fossil fuel expansion, other banks appeal more. We will re-examine our position when the bank reaches a final decision.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Anz Group Price" data-ticker="ASX:ANZ" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/11/03/buy-hold-sell-liontown-ramsay-healthcare-anz-shares/">Buy, hold, sell: Liontown, Ramsay Healthcare, ANZ shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Buy, hold, sell: JB Hi-Fi, Sandfire Resources, Ramsay Health Care shares</title>
                <link>https://www.fool.com.au/2026/10/19/buy-hold-sell-jb-hi-fi-sandfire-resources-ramsay-health-care-shares/</link>
                                <pubDate>Sun, 18 Oct 2026 21:30:00 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1882808</guid>
                                    <description><![CDATA[<p>Let's start the week with some new ratings from market experts. </p>
<p>The post <a href="https://www.fool.com.au/2026/10/19/buy-hold-sell-jb-hi-fi-sandfire-resources-ramsay-health-care-shares/">Buy, hold, sell: JB Hi-Fi, Sandfire Resources, Ramsay Health Care shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">The <strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) <a href="https://www.fool.com.au/2026/10/18/asx-200-utilities-and-healthcare-shares-win-the-week-again/">ascended 1% last week</a> and is down 2.5% over 12 months.</p>



<p class="wp-block-paragraph">Let's start the week with some new ratings from market experts (courtesy <em><a href="https://thebull.com.au/category/18-share-tips/" target="_blank" rel="noreferrer noopener">The Bull</a></em>).&nbsp;</p>



<h2 id="h-jb-hi-fi-ltd-asx-jbh" class="wp-block-heading"><strong>JB Hi Fi Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-jbh/">ASX: JBH</a>)</strong></h2>



<p class="wp-block-paragraph">The JB Hi-Fi share price has tumbled 37% over 12 months. </p>



<p class="wp-block-paragraph">Andrew Wielandt from DP Wealth Advisory has a buy call on this ASX 200 <a href="https://www.fool.com.au/investing-education/consumer-discretionary-shares/">consumer discretionary</a> share.&nbsp;</p>



<p class="wp-block-paragraph">Wielandt said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">This consumer electronics giant continues to show why it's one of Australia's highest quality retailers. </p>



<p class="wp-block-paragraph">The company delivered record total sales of $11.06 billion in full year 2026, up 4.8 per cent on the prior corresponding period. </p>



<p class="wp-block-paragraph">Net profit after tax of $489.9 million increased 6 per cent. The total fully franked <a href="https://www.fool.com.au/definitions/dividend/">dividend</a> of $3.37 was up 22.5 per cent. </p>



<p class="wp-block-paragraph">The company continues to take market share through its low cost operating model, strong brand recognition and leadership across consumer electronics. </p>



<p class="wp-block-paragraph">Our recommendation is supported by a proven management team, strong cash generation and a history of executing well during varying economic conditions.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Jb Hi-Fi Price" data-ticker="ASX:JBH" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<h2 id="h-sandfire-resources-ltd-asx-sfr" class="wp-block-heading"><strong>Sandfire Resources Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sfr/">ASX: SFR</a>)</strong></h2>



<p class="wp-block-paragraph">The Sandfire Resources share price is up 31% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Michael Gable from Fairmont Equities has a hold rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/investing-in-copper-top-asx-copper-shares-of-2022/">copper share</a>.&nbsp;</p>



<p class="wp-block-paragraph">Gable said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">SFR is Australia's largest listed pure play copper producer. Copper demand is increasing in an environment of low supply and this is likely to lead to higher prices. </p>



<p class="wp-block-paragraph">Group sales revenue of $1.7 billion in full year 2026 was up 41 per cent year on year. Profit after tax of $354 million was up 294 per cent. </p>



<p class="wp-block-paragraph">Its final fully franked dividend of 35 cents a share was much higher than the market was expecting. </p>



<p class="wp-block-paragraph">From a charting perspective, the price action for SFR looks bullish and we expect to see a sustainable uptrend from here.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Sandfire Resources Price" data-ticker="ASX:SFR" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</strong></h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price has streaked 77% higher over 12 months. </p>



<p class="wp-block-paragraph">Toby Grimm from Baker Young has a sell rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a>.&nbsp;</p>



<p class="wp-block-paragraph">Grimm explained:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Ramsay Health Care is one of the largest private hospital operators in Australia. It has additional operations in the UK and Europe. </p>



<p class="wp-block-paragraph">Ramsay's operations have improved. Insurer pricing better reflects cost inflation, with higher demand and higher margin procedures prioritised. </p>



<p class="wp-block-paragraph">Yet the industry remains challenging and public sector competitors effectively set input costs without needing to operate profitably. </p>



<p class="wp-block-paragraph">The stock has strongly rallied in the past 12 months to the point we believe it's exposed to a pullback. </p>



<p class="wp-block-paragraph">The forward price/earnings ratio has risen significantly above its 10-year average. </p>



<p class="wp-block-paragraph">Investors may want to consider booking profits and monitor performance from the sidelines.</p>
</blockquote>


<div class="tmf-chart-singleseries" data-title="Ramsay Health Care Price" data-ticker="ASX:RHC" data-range="1y" data-start-date="" data-end-date="" data-comparison-value=""></div>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/10/19/buy-hold-sell-jb-hi-fi-sandfire-resources-ramsay-health-care-shares/">Buy, hold, sell: JB Hi-Fi, Sandfire Resources, Ramsay Health Care shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>2 top ASX blue-chip shares to buy according to experts</title>
                <link>https://www.fool.com.au/2026/10/14/2-top-asx-blue-chip-shares-to-buy-according-to-experts/</link>
                                <pubDate>Tue, 13 Oct 2026 22:30:00 +0000</pubDate>
                <dc:creator><![CDATA[Tristan Harrison]]></dc:creator>
                		<category><![CDATA[Blue Chip Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1881052</guid>
                                    <description><![CDATA[<p>Fund managers think these are compelling picks today. </p>
<p>The post <a href="https://www.fool.com.au/2026/10/14/2-top-asx-blue-chip-shares-to-buy-according-to-experts/">2 top ASX blue-chip shares to buy according to experts</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">Fund managers are always on the hunt for ASX <a href="https://www.fool.com.au/investing-education/blue-chip-shares/">blue-chip</a> shares or smaller stocks that could produce good returns. Sometimes, those experts pick out a very compelling idea. </p>



<p class="wp-block-paragraph">We're going to look at two picks from the portfolio of <strong>WAM Leaders Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wle/">ASX: WLE</a>) that look like strong ideas today.</p>



<p class="wp-block-paragraph">WAM Leaders is a <a href="https://www.fool.com.au/definitions/lic/">listed investment company (LIC)</a> that actively invests in Australian stocks at the larger end of the ASX's <a href="https://www.fool.com.au/definitions/market-capitalisation/">market capitalisation</a> list. </p>



<p class="wp-block-paragraph">Let's look at the two ASX blue-chip shares that WAM Leaders recently highlighted.</p>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading">Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</h2>



<p class="wp-block-paragraph">The fund manager highlighted that last month, the Ramsay Health Care share price rose by 8.6% as investors responded positively to improving momentum in its Australian hospitals business and the progress on the proposed separation of <strong>Ramsay Sante</strong>, its European operations.  </p>



<p class="wp-block-paragraph">WAM Leaders said that the proposed separation of Ramsay Sante is expected to simplify the group and increase management's focus on the core Australian business. </p>



<p class="wp-block-paragraph">The investment team said Ramsay's operational improvement initiatives continue to gain traction, supported by growth in activity, improved operating theatre utilisation, and ongoing cost efficiencies.</p>



<p class="wp-block-paragraph">In September 2026, Ramsay Health Care also completed the <a href="https://www.fool.com.au/tickers/asx-rhc/announcements/2026-09-01/2a1694033/ramsay-completes-acquisition-of-national-capital-private/">acquisition</a> of National Capital Private Hospital and submitted proposals to the Federal Government advocating for broader reform of the private hospital sector.  </p>



<p class="wp-block-paragraph">The investment team maintains a constructive outlook towards Ramsay Health Care as improving operating performance supports further margin recovery and earnings growth.    </p>



<h2 id="h-ansell-ltd-asx-ann" class="wp-block-heading">Ansell Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-ann/">ASX: ANN</a>)</h2>



<p class="wp-block-paragraph">Ansell is the other ASX blue-chip share that WAM Leaders highlighted from the LIC portfolio.</p>



<p class="wp-block-paragraph">The investment team said that Ansell continued to "re-rate" – the <a href="https://www.fool.com.au/definitions/p-e-ratio/">price-earnings (P/E) ratio</a> rose – last month. In September, the Ansell share price rose 11%.  </p>



<p class="wp-block-paragraph">The company has risen significantly since its August <a href="https://www.fool.com.au/2026/08/24/ansell-fy26-earnings-sales-and-profit-surge-boost-outlook/">FY26 results</a>, which revealed earnings and FY27 guidance ahead of market expectations.</p>



<p class="wp-block-paragraph">WAM said healthcare was the key driver of this result, underpinned by strong growth in the Cleanroom business, although performance benefited in part from customer stocking and the timing of price increases. </p>



<p class="wp-block-paragraph">The investment team believe Ansell has managed cost headwinds effectively, including the impact of US tariffs and the Middle East conflict, through disciplined pricing and flexible commercial arrangements.  </p>



<p class="wp-block-paragraph">In terms of the outlook, management remains focused on its core markets, customers, and brands, particularly in the US. WAM thinks this supports the potential for stronger organic growth and further margin improvement.</p>



<p class="wp-block-paragraph">The ASX blue-chip share's <a href="https://www.fool.com.au/investing-education/understanding-balance-sheets-and-pl-statements/">balance sheet</a> also remains in a strong position, according to WAM, providing flexibility for capital management and further investment. </p>



<p class="wp-block-paragraph">WAM concluded: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Ansell remains a core holding in the investment portfolio, with its improving business mix, robust cost management and balance sheet capacity expected to support the company's earnings outlook.</p>
</blockquote>
<p>The post <a href="https://www.fool.com.au/2026/10/14/2-top-asx-blue-chip-shares-to-buy-according-to-experts/">2 top ASX blue-chip shares to buy according to experts</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Buy, hold, sell: Wildcat Resources, Ramsay Health Care, CBA shares</title>
                <link>https://www.fool.com.au/2026/10/13/buy-hold-sell-wildcat-resources-ramsay-health-care-cba-shares/</link>
                                <pubDate>Tue, 13 Oct 2026 00:15:05 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1881087</guid>
                                    <description><![CDATA[<p>The market is down on Tuesday as experts reveal insights into these three companies. </p>
<p>The post <a href="https://www.fool.com.au/2026/10/13/buy-hold-sell-wildcat-resources-ramsay-health-care-cba-shares/">Buy, hold, sell: Wildcat Resources, Ramsay Health Care, CBA shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) shares are down 0.2% to 8,769.2 points on Tuesday. </p>



<p class="wp-block-paragraph"><strong>4DMedical Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-4dx/">ASX: 4DX</a>) shares are the fastest risers of the ASX 200 today, up 4.7%. </p>



<p class="wp-block-paragraph"><strong>Vulcan Energy Resources Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-vul/">ASX: VUL</a>) shares are the biggest fallers, down 8.5%. </p>



<p class="wp-block-paragraph">Meanwhile, on <em><em><a href="https://thebull.com.au/18-share-tips/18-share-tips-12th-october-2026/" target="_blank" rel="noreferrer noopener">The Bu</a><a href="https://thebull.com.au/18-share-tips/18-share-tips-12th-october-2026/">ll</a></em> </em>this week, three experts share their ratings and insights on three ASX shares.</p>



<h2 id="h-wildcat-resources-ltd-asx-wc8" class="wp-block-heading">Wildcat Resources Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wc8/">ASX: WC8</a>)</h2>



<p class="wp-block-paragraph">The Wildcat share price is 24 cents, down 1.2% today and up 15% over 12 months.  </p>



<p class="wp-block-paragraph">Tom Fairchild from Lazarus Capital Partners has a buy rating on this ASX <a href="https://www.fool.com.au/investing-education/lithium-shares/">lithium share</a>.   </p>



<p class="wp-block-paragraph">Fairchild said:  </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">This developer is fast-tracking the Tabba Tabba lithium project near Port Hedland in Western Australia. The project is located near some of the world's largest lithium mines. </p>



<p class="wp-block-paragraph">Macro tailwinds help drive the company's investment case. Electric vehicles and fast growing industrial battery storage drive lithium demand. Australia is the world's largest lithium producer, and the Federal Government offers incentives to grow critical minerals projects. </p>



<p class="wp-block-paragraph">Tabba Tabba hosts 74.1 million tonnes at 1 per cent lithium oxide. A definitive feasibility study is well advanced. Wildcat is drilling the nearby Bolt Cutter lithium discovery and is well funded.</p>
</blockquote>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading">Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price is $54.58, up 1% today and up 71% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Blake Halligan from Gray Perry Wealth Advisers has a hold rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a>.  </p>



<p class="wp-block-paragraph">Halligan said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph" id="h-x-asx-x">Ramsay Health Care is one of the largest private hospital operators in Australia, with additional operations in the UK and Europe. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">Revenue increased 4.2 per cent in constant currency in full year 2006 when compared to the prior corresponding period. Underlying earnings before interest and tax were up 11.8 per cent, supported by improved activity, theatre utilisation and higher margins. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">Management expects further revenue growth and margin improvement in full year 2027. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">Ramsay's scale and exposure to growing health care demand support its longer term outlook. </p>



<p class="wp-block-paragraph" id="h-x-asx-x">However, labour cost pressures and a strong share price rise following the full year results reduce the margin of safety.</p>
</blockquote>



<h2 id="h-commonwealth-bank-of-australia-asx-cba" class="wp-block-heading">Commonwealth Bank of Australia (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-cba/">ASX: CBA</a>)</h2>



<p class="wp-block-paragraph">The Commonwealth Bank of Australia share price is $151.41, up 0.3% today and down 8% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Philippe Bui from Medallion Financial Group has a sell rating on CBA shares. </p>



<p class="wp-block-paragraph">He explained:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">This bank delivered another strong result in full year 2026. The company posted cash profit of $10.982 billion in full year 2026, up 7 per cent on the prior corresponding period. The full year <a href="https://www.fool.com.au/definitions/dividend/">dividend</a> of $5.05, fully franked, was up 4 per cent. </p>



<p class="wp-block-paragraph">CBA's scale, customer franchise and technology investment underpin the company's quality. Nevertheless, we believe the valuation leaves insufficient room for disappointment. </p>



<p class="wp-block-paragraph">Mortgage competition, operating costs and the potential for credit losses to normalise remain risks. </p>



<p class="wp-block-paragraph">We favour taking profits and re-allocating capital to other companies where earnings growth and income offer a more compelling prospective return.</p>
</blockquote>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/10/13/buy-hold-sell-wildcat-resources-ramsay-health-care-cba-shares/">Buy, hold, sell: Wildcat Resources, Ramsay Health Care, CBA shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?</title>
                <link>https://www.fool.com.au/2026/10/06/ramsay-health-care-vs-sonic-healthcare-which-healthcare-stock-is-better-value/</link>
                                <pubDate>Tue, 06 Oct 2026 04:00:00 +0000</pubDate>
                <dc:creator><![CDATA[Laura Stewart]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>
		<category><![CDATA[Assisted]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1879180</guid>
                                    <description><![CDATA[<p>Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my pick for value.</p>
<p>The post <a href="https://www.fool.com.au/2026/10/06/ramsay-health-care-vs-sonic-healthcare-which-healthcare-stock-is-better-value/">Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<h2 id="h-ramsay-health-care-vs-sonic-healthcare-shares" class="wp-block-heading">Ramsay Health Care vs Sonic Healthcare shares</h2>



<p class="wp-block-paragraph">If you're weighing up <strong>Ramsay Health Care Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) and <strong>Sonic Healthcare Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-shl/">ASX: SHL</a>) shares, you're not alone — these two are among the brightest lights in Australian healthcare. Yet, their business models, <a title="What are dividends?" href="https://www.fool.com.au/definitions/dividend/">dividend</a> policies and current market valuations are quite different. For value-seeking investors, there's a lot to unpack, so let's compare their fundamentals, dividend history, recent share price performance and what I think is the smarter buy right now.</p>



<h2 id="h-the-case-for-ramsay-health-care" class="wp-block-heading">The case for Ramsay Health Care</h2>



<p class="wp-block-paragraph">Ramsay Health Care is one of the world's largest private hospital operators, with a vast <a href="https://www.fool.com.au/ideal-number-stocks/" title="What is the ideal number of shares to have in a portfolio?">portfolio</a> spanning around 500 facilities — including hospitals, day surgeries, clinics, and mental health services — across 11 countries. Beyond Australia, Ramsay has substantial operations in Europe and the UK, and, according to its company profile, derives most of its revenue from Australia and Europe. This makes it a genuine global healthcare heavyweight, with a long track record in running complex, capital-intensive medical infrastructure.</p>



<p class="wp-block-paragraph">A couple of key numbers stand out. First, Ramsay's market cap sits at $12.58 billion, above Sonic's, marking it as the larger of the two companies. Its P/E ratio is 41.00, reflecting a rich valuation, especially compared to most of the market. Dividend hunters will note its 1.63% yield, but every cent of that payout is fully franked (100%). Its dividend per share for the most recent period was $0.97, again, all franked. </p>



<h2 id="h-the-case-for-sonic-healthcare" class="wp-block-heading">The case for Sonic Healthcare</h2>



<p class="wp-block-paragraph">Sonic Healthcare is a global leader in pathology and diagnostic services. It's the largest private medical laboratory and pathology provider in key markets including Australia, the UK, Germany, and Switzerland. Most of Sonic's revenue comes from pathology, but the business also has a significant footprint in diagnostic imaging and medical centre operations in Australia, making it a diversified diagnostics powerhouse.</p>



<p class="wp-block-paragraph">Fundamentally, Sonic's story right now is quite different to Ramsay's. Its market capitalisation is $9.20 billion, a fair bit smaller than Ramsay's. But here's where things get interesting for value investors: its P/E ratio is 15.44, easily less than half of Ramsay's, suggesting Sonic shares are much more modestly valued at current earnings levels. Its dividend yield is a chunky 5.69%, and while only 60% franked for the latest payout, that's still a potentially appealing income stream. Recent dividends have totalled $1.08 per share.</p>



<h2 id="h-valuation-comparison" class="wp-block-heading">Valuation comparison</h2>



<p class="wp-block-paragraph">With several key differences apparent, here's how Ramsay and Sonic line up on the numbers that matter for value-focused investors:</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><th><strong>Metric</strong></th><th><strong>Ramsay Health Care</strong></th><th><strong>Sonic Healthcare</strong></th></tr><tr><td>Market Cap</td><td>$12.58 billion</td><td>$9.20 billion</td></tr><tr><td>P/E Ratio</td><td>41.00</td><td>15.44</td></tr><tr><td>Dividend Yield</td><td>1.63% (100% franked)</td><td>5.69% (60% franked)</td></tr><tr><td>Dividend per share (most recent)</td><td>$0.97</td><td>$1.08</td></tr><tr><td>Earnings per share</td><td>1.358</td><td>1.230</td></tr><tr><td>Year to Date Return</td><td>64.7%</td><td>-11.2%</td></tr></tbody></table></figure>



<p class="wp-block-paragraph">Note: Ramsay's reported P/E ratio may be based on a different earnings measure (e.g. underlying or forward earnings) than the EPS figure shown, which is why they may appear inconsistent.</p>



<p class="wp-block-paragraph">Simply put, if I'm judging pure valuation metrics, Sonic Healthcare looks much more attractively priced relative to its earnings and offers a much higher dividend yield, albeit with less franking than Ramsay. Ramsay's high P/E suggests the market is baking in a lot of future growth or sees it as much lower risk — or possibly a bit of both.</p>



<h2 id="h-recent-share-price-momentum" class="wp-block-heading">Recent share price momentum</h2>



<p class="wp-block-paragraph">Comparing recent share price performance up to1 October 2026:</p>



<ul class="wp-block-list">
<li>Ramsay Health Care closed at $54.48 on 1 Oct 2026, down 2.16% on the day but boasting impressive momentum over 2026 with a year-to-date return of 64.7%.</li>



<li>Sonic Healthcare finished at $18.61 on 1 Oct 2026, also dropping 2.00% that day, and is down 11.2% for the year to date.</li>
</ul>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Over the past year, Ramsay has surged ahead and Sonic has gone backwards. For investors looking for momentum and the market's latest vote of confidence, Ramsay clearly wears the crown for 2026 so far.</p>



<h2 id="h-which-is-the-better-buy" class="wp-block-heading">Which is the better buy?</h2>



<p class="wp-block-paragraph">For me, as a value-seeking investor, Sonic Healthcare is the better buy right now. Here's why: Sonic's P/E ratio of 15.44 is far lower than Ramsay's 41.00, and yet its earnings per share are pretty similar. Even better, Sonic's dividend yield is well over three times Ramsay's (5.69% vs 1.63%), though franking is only 60% versus Ramsay's full 100%. </p>



<p class="wp-block-paragraph">Ramsay has had a great run this year, reflected in its huge year-to-date return, but that's precisely why I'd be cautious about buying it now – it's probably priced for perfection. Sonic, meanwhile, has lagged in the share price stakes and may well be out of favour, but it's this relative unloved status that gives it value appeal. Its business is less capital intensive, cash-generative and, in my eyes, looks like a classic opportunity for patient investors to scoop up a top ASX healthcare stock at a fair valuation, with a strong, fully-funded dividend yield to boot.</p>



<p class="wp-block-paragraph">So, if I had to buy one for value today, my pick would be Sonic Healthcare.</p>
<p>The post <a href="https://www.fool.com.au/2026/10/06/ramsay-health-care-vs-sonic-healthcare-which-healthcare-stock-is-better-value/">Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Buy, hold, sell: Woodside, Life360, Ramsay Health Care shares</title>
                <link>https://www.fool.com.au/2026/09/29/buy-hold-sell-woodside-life360-ramsay-health-care-shares/</link>
                                <pubDate>Tue, 29 Sep 2026 04:14:03 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1878111</guid>
                                    <description><![CDATA[<p>New stock tips for investors this week. </p>
<p>The post <a href="https://www.fool.com.au/2026/09/29/buy-hold-sell-woodside-life360-ramsay-health-care-shares/">Buy, hold, sell: Woodside, Life360, Ramsay Health Care shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) shares are just inside the green on Tuesday as the market awaits the next interest rate announcement at 2:30pm. </p>



<p class="wp-block-paragraph">Analysts are pricing in <a href="https://www.asx.com.au/markets/trade-our-derivatives-market/futures-market/rba-rate-tracker">a 92% bet</a> that the Reserve Bank of Australia (RBA) will lift the cash rate by 0.25% to 4.6%.&nbsp;</p>



<p class="wp-block-paragraph">Persistently high inflation, rising oil prices due to the Iran-US conflict, soaring bond yields to multi-decade highs, and rock-bottom productivity growth in Australia are among the reasons interest rates are expected to rise again.</p>



<p class="wp-block-paragraph">Experts say there could even be another 0.25% bump in November, which would be the fifth in the 2026 calendar year.&nbsp;</p>



<p class="wp-block-paragraph">Meanwhile, experts offer their ratings and thoughts on three ASX 200 shares.&nbsp;</p>



<h2 id="h-woodside-energy-group-ltd-asx-wds" class="wp-block-heading"><strong>Woodside Energy Group Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wds/">ASX: WDS</a>)</strong></h2>



<p class="wp-block-paragraph">The Woodside share price is $31.21, down 1.8% today and up 33% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">John Athanasiou from Red Leaf Securities has a buy rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/asx-energy-shares/">energy share</a>.&nbsp;</p>



<p class="wp-block-paragraph">Athanasiou said (courtesy of<a href="https://thebull.com.au/category/analysis-opinion/18-share-tips/"> <em>The Bull</em>)</a>:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Woodside offers exposure to recent elevated global energy prices amid supply disruptions and continuing Middle East tensions.</p>



<p class="wp-block-paragraph">Stronger realised prices should support near term cash flow and dividends.</p>



<p class="wp-block-paragraph">A major risk is an easing of geopolitical tensions and a corresponding fall in crude oil prices.</p>



<p class="wp-block-paragraph">However, the company delivered a solid interim result. Operating revenue of $7.446 billion in the first half of 2026 was up 13 per cent on the prior corresponding period. Underlying net profit after tax of $1.334 billion was up 7 per cent.</p>



<p class="wp-block-paragraph">The Scarborough energy project is almost completed. </p>
</blockquote>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</strong></h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price is $55.77, up 0.4% today and up 77% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Morgans has a hold rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a>.&nbsp;</p>



<p class="wp-block-paragraph">The broker said:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">Ramsay Santé's Capital Markets Day provided detail on its new "Connecting Care 2030" strategy ahead of the proposed demerger from RHC.</p>



<p class="wp-block-paragraph">The strategy targets 2-3% revenue growth and stable EBITDA margins in FY27, followed by c3% revenue growth and gradual margin improvement to FY29.</p>



<p class="wp-block-paragraph">While we view the strategy as credible, the outlook points to gradual rather than significant earnings growth, with tariff constraints remaining a key headwind.</p>



<p class="wp-block-paragraph">For RHC shareholders, the proposed in-specie distribution should simplify the group and provide direct ownership of Santé through ASX-tradeable CDIs. </p>
</blockquote>



<h2 id="h-life360-inc-asx-360" class="wp-block-heading"><strong>Life360 Inc (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-360/">ASX: 360</a>)</strong></h2>



<p class="wp-block-paragraph">The Life360 share price is $18.95, down 1.9% today and down 64% over 12 months.&nbsp;</p>



<p class="wp-block-paragraph">Michael Gable from Fairmont Equities has a sell rating on this ASX 200 <a href="https://www.fool.com.au/investing-education/technology/">tech share</a>.&nbsp;</p>



<p class="wp-block-paragraph">Gable commented:&nbsp;</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">The company posted a 38 per cent increase in revenue in the second quarter of 2026 when compared to the prior corresponding period. Total subscription revenue was up 31 per cent.</p>



<p class="wp-block-paragraph">However, the share price has fallen from $29.48 on August 10 to trade at $19.44 on September 24.</p>



<p class="wp-block-paragraph">We believe the business is vulnerable to increasing competition. Any earnings disappointments moving forward may further pressure the share price.</p>



<p class="wp-block-paragraph">Investors may want to consider cashing in some gains. </p>
</blockquote>
<p>The post <a href="https://www.fool.com.au/2026/09/29/buy-hold-sell-woodside-life360-ramsay-health-care-shares/">Buy, hold, sell: Woodside, Life360, Ramsay Health Care shares</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Expert names &#039;undervalued&#039; ASX 200 healthcare stock to buy today</title>
                <link>https://www.fool.com.au/2026/09/29/expert-names-undervalued-asx-200-healthcare-stock-to-buy-today/</link>
                                <pubDate>Tue, 29 Sep 2026 01:12:32 +0000</pubDate>
                <dc:creator><![CDATA[Bernd Struben]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1877956</guid>
                                    <description><![CDATA[<p>A top fundie expects more outperformance from this resurgent ASX healthcare share.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/29/expert-names-undervalued-asx-200-healthcare-stock-to-buy-today/">Expert names &#039;undervalued&#039; ASX 200 healthcare stock to buy today</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>Ramsay Health Care Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) shares are edging lower today. </p>



<p class="wp-block-paragraph">Shares in the <strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare</a> stock closed yesterday trading for $55.56. In morning trade on Tuesday, shares are changing hands for $55.49 apiece, down 0.1%. </p>



<p class="wp-block-paragraph">For some context, the ASX 200 is up 0.2% at this same time.  </p>



<p class="wp-block-paragraph">Taking a step back, Ramsay Health Care shares have surged 75.9% since this time last year, smashing the 12-month 1.9% losses posted by the benchmark index. </p>



<p class="wp-block-paragraph">And that's not including the two fully-franked dividends, totalling 91 cents a share that the ASX 200 healthcare stock paid out over the full year. At the current share price, Ramsay Healthcare trades on a fully-franked trailing dividend yield of 1.6%.</p>



<p class="wp-block-paragraph">Despite that strong outperformance, Merlon Capital Partners co-portfolio manager Joey Mui believes the stock is still <a href="https://www.afr.com/markets/equity-markets/this-fundie-s-strategy-look-for-the-asx-s-undervalued-gems-20260924-p60sij" target="_blank" rel="noopener">undervalued</a> (courtesy of the <em>Australian Financial Review</em>).   </p>



<p class="wp-block-paragraph">Here's why.</p>



<h2 id="h-asx-200-healthcare-stock-with-further-upside" class="wp-block-heading"><strong>ASX 200 healthcare stock with further upside</strong></h2>



<p class="wp-block-paragraph">Asked which stock his fund owns that's most undervalued by the market, Mui pointed to private healthcare provider Ramsay Health Care. </p>



<p class="wp-block-paragraph">"We believe Ramsay is still significantly undervalued," he said. </p>



<p class="wp-block-paragraph">Explaining his bullish outlook on the resurgent ASX 200 healthcare stock, Mui said:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">The market has been cautious about its ability to offset inflation, but we see a strong opportunity to lift margins – through higher theatre utilisation, a better mix of specialities, and cost indexation from insurers. The new management team under Natalie Davis is executing on these strategies well. </p>
</blockquote>



<h2 id="h-what-s-the-latest-from-ramsay-health-care" class="wp-block-heading"><strong>What's the latest from Ramsay Health Care?</strong></h2>



<p class="wp-block-paragraph">Ramsay Health Care shares closed up a blistering 13.7% on 27 August, following the release of the company's full-year FY 2026 results. </p>



<p class="wp-block-paragraph">For the 12 months to 30 June, the ASX 200 healthcare stock reported underlying earnings before tax (EBIT) of $1.16 billion, up 11.5% year on year. </p>



<p class="wp-block-paragraph">And on the bottom line, Ramsay achieved an underlying net profit after tax (NPAT) of $364 million, up 19.3% from FY 2025.</p>



<p class="wp-block-paragraph">Commenting on the strong results, Ramsay Health Care CEO and managing director Natalie Davis said, "FY26 was a year of continued improvement and delivery for Ramsay, with group underlying NPAT up 23% (in constant currency) year-on-year, all regions delivering EBIT growth, high patient NPS and clinical excellence across the group." </p>



<p class="wp-block-paragraph">Looking to what's ahead for the company in FY 2027, Davis added:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We will continue to build on Ramsay's clinical excellence in Australia for the benefit of our patients, by investing in clinical innovation and connecting hospital and healthcare services in our priority therapeutic areas – cardiology, orthopaedics and cancer care, to be Australia's most trusted leading healthcare provider and to grow long-term shareholder value.</p>
</blockquote>
<p>The post <a href="https://www.fool.com.au/2026/09/29/expert-names-undervalued-asx-200-healthcare-stock-to-buy-today/">Expert names &#039;undervalued&#039; ASX 200 healthcare stock to buy today</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>5 things to watch on the ASX 200 on Thursday</title>
                <link>https://www.fool.com.au/2026/09/24/5-things-to-watch-on-the-asx-200-on-thursday-24-september-2026/</link>
                                <pubDate>Wed, 23 Sep 2026 21:14:27 +0000</pubDate>
                <dc:creator><![CDATA[James Mickleboro]]></dc:creator>
                		<category><![CDATA[ASX Share Market News]]></category>
		<category><![CDATA[trending]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1876566</guid>
                                    <description><![CDATA[<p>It looks set to be a tough session for Aussie investors.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/24/5-things-to-watch-on-the-asx-200-on-thursday-24-september-2026/">5 things to watch on the ASX 200 on Thursday</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">On Wednesday, the&nbsp;<strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) was on form and edged higher. The benchmark index rose 0.1% to 8,765.3 points.</p>



<p class="wp-block-paragraph">Will the market be able to build on this on Thursday? Here are five things to watch:</p>



<h2 class="wp-block-heading"><strong>ASX 200 expected to sink</strong></h2>



<p class="wp-block-paragraph">It looks set to be a tough session for Australian investors on Thursday following a poor night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 104 points or 1.2% lower this morning. In the United States, the Dow Jones fell 0.7%, the S&amp;P 500 dropped 0.75%, and the Nasdaq was 1.1% lower.</p>



<h2 class="wp-block-heading"><strong>ASX 200 shares paying dividends</strong></h2>



<p class="wp-block-paragraph">A number of ASX 200 shares are rewarding their shareholders with dividends on Thursday. This includes <strong>PLS Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-pls/">ASX: PLS</a>), <strong>Telstra Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-tls/">ASX: TLS</a>), <strong>ResMed Inc.</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rmd/">ASX: RMD</a>), <strong>Ramsay Health Care Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>), and <strong>Rio Tinto Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rio/">ASX: RIO</a>). The latter is paying a fully franked $2.96 per share interim dividend later today.</p>



<h2 class="wp-block-heading"><strong>Oil prices rise</strong></h2>



<p class="wp-block-paragraph">ASX 200 energy shares <strong>Woodside Energy Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wds/">ASX: WDS</a>) and <strong>Santos Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sto/">ASX: STO</a>) could have a good session after oil prices rose overnight. <a href="https://www.bloomberg.com/energy">According to Bloomberg</a>, the WTI crude oil price is up 2.4% to US$92.70 a barrel and the Brent crude oil price is up 4.1% to US$103.35 a barrel. Doubts over a US-Iran peace deal were behind the rise.</p>



<h2 id="h-buy-nufarm-shares" class="wp-block-heading"><strong>Buy Nufarm shares</strong></h2>



<p class="wp-block-paragraph"><strong>Nufarm Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nuf/">ASX: NUF</a>) shares could be a good option for investors according to Bell Potter. This morning, the broker has retained its buy rating on the agricultural chemicals company's shares with an improved price target of $3.90 (from $3.75). It said: "Our Buy rating is unchanged. In FY26e NUF has delivered a result that was consistent with our expectations, while incurring costs related to plant outages that were not expected. The underlying performance looks to be stronger than what is implied at the headline, with material YoY growth in Seeds and the basis of the next leg of cost outs now articulated."</p>



<h2 class="wp-block-heading"><strong>Gold price falls</strong></h2>



<p class="wp-block-paragraph">It could be a poor day for ASX 200 gold shares <strong>Newmont Corporation</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nem/">ASX: NEM</a>) and <strong>Northern Star Resources Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nst/">ASX: NST</a>) on Thursday after the gold price fell overnight. According to CNBC, the <a href="https://www.cnbc.com/quotes/@GC.1">gold futures price</a> is down 1.2% to US$4,323.9 an ounce. A rebound in oil prices appears to have led to increased US rate hike bets.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/24/5-things-to-watch-on-the-asx-200-on-thursday-24-september-2026/">5 things to watch on the ASX 200 on Thursday</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?</title>
                <link>https://www.fool.com.au/2026/09/23/telix-pharmaceuticals-vs-ramsay-healthcare-which-asx-healthcare-stock-made-investors-richer-in-2026/</link>
                                <pubDate>Tue, 22 Sep 2026 23:42:10 +0000</pubDate>
                <dc:creator><![CDATA[Samantha Menzies]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1876145</guid>
                                    <description><![CDATA[<p>And find out which has the strongest upside ahead.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/23/telix-pharmaceuticals-vs-ramsay-healthcare-which-asx-healthcare-stock-made-investors-richer-in-2026/">Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>Telix Pharmaceuticals Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-tlx/">ASX: TLX</a>) and <strong>Ramsay Health Care Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) are two <a href="https://www.fool.com.au/investing-education/healthcare-shares/">ASX healthcare</a> powerhouse stocks with entirely different core businesses. </p>



<p class="wp-block-paragraph">Telix is a commercial-stage biopharmaceutical company that is focused on the ongoing development of diagnostic and therapeutic products using targeted radiation. This process treats cancerous or diseased cells without attacking healthy tissue at the same time, like many traditional cancer medicines. </p>



<p class="wp-block-paragraph">Meanwhile, Ramsay is a large global private healthcare provider that has over 500 facilities across 11 countries. It operates private hospitals, day surgeries, primary care clinics, diagnostic and imaging centres, mental health facilities, pharmacies, and some in-home and community care services.   </p>



<p class="wp-block-paragraph">What the two businesses do have in common is that they both generate a significant portion of their revenues outside Australia, they're both reliant on regulatory approvals, and they've both outperformed the <strong>S&amp;P/ASX 200 Index </strong>(ASX: XJO) and the <strong>S&amp;P/ASX 200 Health Care Index </strong>(ASX: XHJ) over the past 12 months.   </p>



<p class="wp-block-paragraph">And this is particularly significant given the amount of headwinds and <a href="https://www.fool.com.au/definitions/volatility/">volatility</a> the ASX healthcare sector experienced through late-2025 and into 2026. </p>



<p class="wp-block-paragraph">While many shares suffered from intense volatility driven by unstable <a href="https://www.fool.com.au/investing-education/inflation/">inflation</a> and a general investor rotation away from the healthcare sector, both Telix and Ramsay shares bucked the trend.</p>



<p class="wp-block-paragraph">But which stock has made investors richer so far in 2026? And which has the strongest upside ahead?</p>



<p class="wp-block-paragraph">Let's take a look. </p>



<h2 id="h-telix-vs-ramsay-which-asx-healthcare-stock-has-climbed-higher-in-2026" class="wp-block-heading"><strong>Telix vs Ramsay: Which ASX healthcare stock has climbed higher in 2026?</strong></h2>



<p class="wp-block-paragraph">At the close of the ASX on Tuesday afternoon, Telix shares had climbed another 7% to $16.79 a piece. That brings the company's year-to-date increase to an impressive 48%.</p>



<p class="wp-block-paragraph">But it hasn't been smooth sailing for Telix shares this year. After tumbling to a three-year low of $8.63 in mid-February, the share price started rebounding in peaks and troughs. Telix shares have fluctuated anywhere between $8.63 and $17.85 this year.</p>



<p class="wp-block-paragraph">Meanwhile, Ramsay shares closed the day in the red, down slightly by around 0.2% to $55.50. But the share price trajectory is quite different. Despite the dip, the shares are now up an impressive 60% year to date.</p>



<p class="wp-block-paragraph">Ramsay shares started climbing higher in late 2025 and continued increasing through to early 2026. The rally has been pretty steady and consistent, reaching a two-year high of $55.61 on Monday.</p>



<p class="wp-block-paragraph">The verdict: Ramsay shares have made investors richer in 2026 so far.</p>



<h2 id="h-what-do-brokers-tip-next-for-telix-shares" class="wp-block-heading"><strong>What do brokers tip next for Telix shares?</strong></h2>



<p class="wp-block-paragraph">The experts are still incredibly bullish on Telix shares over the next 12 months. TradingView data shows the majority (13 out of 15) have a buy/strong buy rating on the ASX healthcare stock.  </p>



<p class="wp-block-paragraph">The $25.63 average target price implies an upside of around 53% at the time of writing.&nbsp;</p>



<p class="wp-block-paragraph">But some are even more optimistic and forecast the stock could jump 88% to $31.53 over the next 12 months.</p>



<h2 id="h-what-do-brokers-tip-next-for-ramsay-shares" class="wp-block-heading"><strong>What do brokers tip next for Ramsay shares?</strong></h2>



<p class="wp-block-paragraph">While Ramsay shares may be the winner in terms of which of the two has made investors richer year to date, its 12-month outlook isn't as positive as Telix's.</p>



<p class="wp-block-paragraph">In fact, analyst forecasts suggest that the ASX healthcare stock could now be trading above fair value.</p>



<p class="wp-block-paragraph">TradingView data shows the majority (12 out of 17) have a hold rating on Ramsay shares. And the $51.36 average target price now implies around a 7% downside, at the time of writing. </p>
<p>The post <a href="https://www.fool.com.au/2026/09/23/telix-pharmaceuticals-vs-ramsay-healthcare-which-asx-healthcare-stock-made-investors-richer-in-2026/">Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike</title>
                <link>https://www.fool.com.au/2026/09/20/asx-200-healthcare-shares-lead-a-weaker-market-amid-82-chance-of-a-rate-hike/</link>
                                <pubDate>Sat, 19 Sep 2026 21:00:00 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[ASX Share Market News]]></category>
		<category><![CDATA[Healthcare Shares]]></category>
		<category><![CDATA[trending]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1875095</guid>
                                    <description><![CDATA[<p>Healthcare shares gained 3.76% while the ASX 200 fell 0.11% last week. </p>
<p>The post <a href="https://www.fool.com.au/2026/09/20/asx-200-healthcare-shares-lead-a-weaker-market-amid-82-chance-of-a-rate-hike/">ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">ASX&nbsp;200&nbsp;<a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare&nbsp;shares</a>&nbsp;led the&nbsp;11&nbsp;<a href="https://www.fool.com.au/investing-education/market-sectors-guide/">market sectors</a> last week with a 3.76% gain over the five trading days.</p>



<p class="wp-block-paragraph">The broader&nbsp;<strong>S&amp;P/ASX 200 Index&nbsp;</strong>(ASX: XJO) slipped 0.11% over the week to 8,731.2 points on Friday.</p>



<p class="wp-block-paragraph">The market was volatile on <a href="https://www.asx.com.au/markets/trade-our-derivatives-market/futures-market/rba-rate-tracker">increased bets</a> of another <a href="https://www.fool.com.au/investing-education/interest-rates/">interest rate</a> hike due to persistently high <a href="https://www.fool.com.au/definitions/inflation/">inflation</a>.</p>



<p class="wp-block-paragraph">The market is pricing an 82% chance that the Reserve Bank will lift rates by another 0.25% at the end of the month.</p>



<p class="wp-block-paragraph">Last week, the <a href="https://www.fool.com.au/2026/09/17/the-fed-just-hiked-rates-for-the-first-time-in-3-years-what-does-it-mean-for-asx-investors/">US Fed raised rates for the first time in three years</a>, and Japan also increased rates to a 30-year high.</p>



<p class="wp-block-paragraph">Elevated oil prices due to the US-Iran conflict continue to contribute to stubborn inflation worldwide.</p>



<p class="wp-block-paragraph">Last week, eight of the 11 market sectors finished in the red.</p>



<p class="wp-block-paragraph">Let's review.</p>



<h2 id="h-healthcare-led-the-market-sectors-last-week" class="wp-block-heading">Healthcare led the market sectors last week</h2>



<p class="wp-block-paragraph">Healthcare is continuing its rapid rebound following a 29% slump over the 12 months to early June.</p>



<p class="wp-block-paragraph">The <strong>S&amp;P/ASX 200 Health Care Index</strong>&nbsp;(ASX: XHJ) hit a 9-year low on 3 June.</p>



<p class="wp-block-paragraph">Healthcare shares have ripped 43% since then compared to a 0.6% fall for the ASX 200.</p>



<p class="wp-block-paragraph">The <strong>CSL Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-csl/">ASX: CSL</a>) share price popped 5.08% to $175.59 last week, and it's up 90% since 3 June.&nbsp;</p>



<p class="wp-block-paragraph"><strong>Resmed CDI</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rmd/">ASX: RMD</a>) shares rose 5.15% to $31.87, and are 23% higher since 3 June.&nbsp;</p>



<p class="wp-block-paragraph"><strong>Pro Medicus Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-pme/">ASX: PME</a>) shares jumped 3.18% to $169.57 on Friday, and are up 6% since 3 June.&nbsp;</p>



<p class="wp-block-paragraph">The&nbsp;<strong>Ramsay Health Care Ltd&nbsp;</strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) share price lifted 3.44% to $55.39, and is up 52% since 3 June.&nbsp;</p>



<p class="wp-block-paragraph"><strong>Sonic Healthcare Ltd&nbsp;</strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-shl/">ASX: SHL</a>) shares edged 1.26% higher to $19.24, and are up 2% since 3 June.</p>



<p class="wp-block-paragraph"><strong>Telix Pharmaceuticals Ltd</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-tlx/">ASX: TLX</a>) shares jumped 13.91% to $17.85 on Friday, and are up 46% since 3 June.</p>



<p class="wp-block-paragraph">The <strong>4DMedical Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-4dx/">ASX: 4DX</a>) share price leapt 28.27% to $4.31, and is up 14% since 3 June.&nbsp;</p>



<p class="wp-block-paragraph">Chemist warehouse owner <strong>Sigma Healthcare Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sig/">ASX: SIG</a>) bucked the trend last week.</p>



<p class="wp-block-paragraph">Sigma Healthcare shares fell 3.04% to $2.55, and are 12% lower since 3 June.&nbsp;</p>



<p class="wp-block-paragraph">The&nbsp;<strong>Cochlear Ltd</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-coh/">ASX: COH</a>) share price also fell 0.18% to $133.90 last week.</p>



<p class="wp-block-paragraph">Cochlear shares have recovered 41% since 3 June.&nbsp;</p>



<h2 id="h-asx-200-market-sector-snapshot" class="wp-block-heading">ASX 200 market sector snapshot</h2>



<p class="wp-block-paragraph">Here's how the 11 market sectors stacked up last week, according to CommSec data.</p>



<p class="wp-block-paragraph">Over the five trading days:</p>



<figure class="wp-block-table"><table><tbody><tr><td><strong>S&amp;P/ASX 200</strong>&nbsp;<strong>market sector</strong></td><td><strong>Change last week</strong></td></tr><tr><td><strong>Healthcare&nbsp;</strong>(ASX: XHJ)</td><td>3.76%</td></tr><tr><td><strong>Utilities</strong>&nbsp;(ASX: XUJ)</td><td>0.5%</td></tr><tr><td><strong>Communication&nbsp;</strong>(ASX: XTJ)</td><td>0.03%</td></tr><tr><td><strong>Industrials&nbsp;</strong>(ASX: XNJ) </td><td>(0.02%)</td></tr><tr><td><strong>Consumer Discretionary&nbsp;</strong>(ASX: XDJ)</td><td>(0.14%)</td></tr><tr><td><strong>Financials&nbsp;</strong>(ASX: XFJ)</td><td>(0.21%)</td></tr><tr><td><strong>Materials&nbsp;</strong>(ASX: XMJ)</td><td>(0.32%)</td></tr><tr><td><strong>Consumer Staples</strong>&nbsp;(ASX: XSJ)</td><td>(0.74%)</td></tr><tr><td><strong>Information Technology&nbsp;</strong>(ASX: XIJ)</td><td>(0.81%)</td></tr><tr><td><strong>Energy </strong>(ASX: XEJ)</td><td>(1.29%)</td></tr><tr><td><strong>A-REIT</strong>&nbsp;(ASX: XPJ)</td><td>(1.89%)</td></tr></tbody></table></figure>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/09/20/asx-200-healthcare-shares-lead-a-weaker-market-amid-82-chance-of-a-rate-hike/">ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>6 ASX 200 shares boosted by brokers this week</title>
                <link>https://www.fool.com.au/2026/09/17/6-asx-200-shares-boosted-by-brokers-this-week/</link>
                                <pubDate>Thu, 17 Sep 2026 05:58:00 +0000</pubDate>
                <dc:creator><![CDATA[Bronwyn Allen]]></dc:creator>
                		<category><![CDATA[Broker Notes]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1874654</guid>
                                    <description><![CDATA[<p>Brokers have increased their ratings on CSL, NAB, Ramsay Health Care, and others this week. </p>
<p>The post <a href="https://www.fool.com.au/2026/09/17/6-asx-200-shares-boosted-by-brokers-this-week/">6 ASX 200 shares boosted by brokers this week</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph" id="h-brokers-have-increased-their-ratings-on-x-x-and-others-this-week"><strong>S&amp;P/ASX 200 Index </strong>(ASX: XJO) shares are 0.2% higher at 8,714.9 points on Thursday.  </p>



<p class="wp-block-paragraph">Meanwhile, brokers have lifted their ratings on several ASX 200 shares this week.  </p>



<p class="wp-block-paragraph">Let's review.&nbsp;</p>



<h2 id="h-csl-ltd-asx-csl" class="wp-block-heading"><strong>CSL Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-csl/">ASX: CSL</a>)</strong></h2>



<p class="wp-block-paragraph">The CSL share price is $177.29, up 1.7% today.</p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare share</a> has ripped 32%.</p>



<p class="wp-block-paragraph">RBC Capital upgraded CSL shares to a buy rating on Tuesday. </p>



<p class="wp-block-paragraph">The broker raised its 12-month price target substantially from $148 to $213.</p>



<p class="wp-block-paragraph">This implies a potential 20% upside ahead. </p>



<h2 id="h-national-australia-bank-ltd-asx-nab" class="wp-block-heading"><strong>National Australia Bank Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nab/">ASX: NAB</a>)</strong></h2>



<p class="wp-block-paragraph">The NAB share price is $38.91, up 2.3% today. </p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 <a href="https://www.fool.com.au/investing-education/bank-shares/">bank share</a> has fallen 1%. </p>



<p class="wp-block-paragraph">Citi upgraded NAB shares to a buy rating yesterday. </p>



<p class="wp-block-paragraph">The broker increased its 12-month price target from $40 to $42.10.</p>



<p class="wp-block-paragraph">This suggests a potential 8% upside ahead.</p>



<h2 id="h-lottery-corporation-ltd-asx-tlc" class="wp-block-heading"><strong>Lottery Corporation Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-tlc/">ASX: TLC</a>)</strong></h2>



<p class="wp-block-paragraph">The Lottery Corporation share price is $4.86, up 0.7% today.</p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 <a href="https://www.fool.com.au/investing-education/consumer-discretionary-shares/">consumer discretionary</a> share has fallen 9%.</p>



<p class="wp-block-paragraph">Morgans upgraded Lottery Corporation shares to a buy call today. </p>



<p class="wp-block-paragraph">The broker reduced its 12-month price target from $5.60 to $5.40. </p>



<p class="wp-block-paragraph">This implies a potential 11% upside ahead. </p>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading"><strong>Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</strong></h2>



<p class="wp-block-paragraph">The Ramsay Health Care share price is $55.06, up 0.4% today.</p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 healthcare share has risen 23%.</p>



<p class="wp-block-paragraph">RBC Capital upgraded Ramsay Health Care shares to a buy call this week. </p>



<p class="wp-block-paragraph">The broker increased its 12-month price target significantly from $52 to $68. </p>



<p class="wp-block-paragraph">This indicates potential capital gains of 23% over the next year.  </p>



<h2 id="h-challenger-ltd-asx-cgf" class="wp-block-heading"><strong>Challenger Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-cgf/">ASX: CGF</a>)</strong></h2>



<p class="wp-block-paragraph">The Challenger share price is $10.09, down 1.9% today.</p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 <a href="https://www.fool.com.au/investing-education/financial-shares/">financial share</a> has increased 4%.</p>



<p class="wp-block-paragraph">UBS upgraded Challenger shares to a buy rating with a $11.50 price target. </p>



<p class="wp-block-paragraph">This suggests a potential 14% upside ahead. </p>



<h2 id="h-james-hardie-industries-plc-asx-jhx" class="wp-block-heading"><strong>James Hardie Industries Plc (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-jhx/">ASX: JHX</a>)</strong></h2>



<p class="wp-block-paragraph">The James Hardie share price is $37.38, up 0.2% today.</p>



<p class="wp-block-paragraph">Over the past month, this ASX 200 materials share has fallen 15%.</p>



<p class="wp-block-paragraph">Morgans upgraded James Hardie shares to an accumulate rating yesterday.</p>



<p class="wp-block-paragraph">The broker shaved its 12-month price target from $45 to $43.</p>



<p class="wp-block-paragraph">This suggests potential capital growth of 15% over the next year.&nbsp;</p>



<p class="wp-block-paragraph">Morgans said: </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">The positive company story and the growth trajectory are only partially offset by the tough macro, a 75bps rise in the 30-year mortgage rate over the past six months, and a peer multiple de-rate. </p>



<p class="wp-block-paragraph">On this basis we upgrade to an Accumulate rating, whilst moderating our target price to A$43.00 (from A$45.00).</p>
</blockquote>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/09/17/6-asx-200-shares-boosted-by-brokers-this-week/">6 ASX 200 shares boosted by brokers this week</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded</title>
                <link>https://www.fool.com.au/2026/09/17/csl-resmed-and-more-see-which-asx-health-stocks-rbc-capital-markets-has-upgraded/</link>
                                <pubDate>Wed, 16 Sep 2026 20:00:00 +0000</pubDate>
                <dc:creator><![CDATA[Cameron England]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1874108</guid>
                                    <description><![CDATA[<p>This sector is coming back into favour.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/17/csl-resmed-and-more-see-which-asx-health-stocks-rbc-capital-markets-has-upgraded/">CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">RBC Capital Markets has released a new report on the Australian-listed healthcare sector, upgrading five major stocks to an outperform rating in the process. </p>



<p class="wp-block-paragraph">The broking house said healthcare had performed "generally much better than we had feared" across the August reporting season.</p>



<p class="wp-block-paragraph">They added:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">A combination of revenue beats and cost control drove earnings beats for most companies and we are now expecting positive earnings growth across the sector. While most of the sector has enjoyed a re-rating over the past 2 months, we believe a number of stocks could re-rate even further given their earnings growth outlook, appealing relative valuations and attractiveness of the healthcare sector in light of macroeconomic uncertainty.</p>
</blockquote>



<p class="wp-block-paragraph">As a result of this positivity, RBC has upgraded five stocks to an outperform rating and maintained that rating on one more.</p>



<p class="wp-block-paragraph">Let's see who they like. </p>



<h2 id="h-csl-ltd-asx-csl" class="wp-block-heading">CSL Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-csl/">ASX: CSL</a>)</h2>



<p class="wp-block-paragraph">RBC said the <a href="https://www.fool.com.au/2026/08/18/csl-shares-surge-18-as-reset-year-points-to-a-return-to-growth/">recent result </a>showed that CSL was regaining market share in the key immunoglobulin sector.</p>



<p class="wp-block-paragraph">The broker said they now believed that "growth in the Behring business can offset the weak outlook in the Seqirus and Vifor business, and enable the company to deliver mid-single digit EPS growth for the next 3 years''.</p>



<p class="wp-block-paragraph">While these growth rates were below historical levels, RBC said they were reasonable compared to other Australian large-cap stocks. </p>



<p class="wp-block-paragraph">RBC has a price target of $213 on CSL shares. </p>



<h2 id="h-resmed-ltd-asx-rmd" class="wp-block-heading">Resmed Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rmd/">ASX: RMD</a>)</h2>



<p class="wp-block-paragraph">The sleep apnoea device company <a href="https://www.fool.com.au/2026/08/07/resmed-posts-strong-q4-earnings-lifts-dividend/">delivered an in-line result</a>, RBC said; however, there was more focus on capital management.</p>



<p class="wp-block-paragraph">The broker is factoring in $1.5 billion in share buybacks per year out to FY31. </p>



<p class="wp-block-paragraph">RBC has a price target of $262 on Resmed shares.</p>



<h2 id="h-ramsay-healthcare-ltd-asx-rhc" class="wp-block-heading">Ramsay Healthcare Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</h2>



<p class="wp-block-paragraph">RBC said Ramsay was being well run, with its recent result showing good revenue growth and cost control.</p>



<p class="wp-block-paragraph">They have valued the company on a demerger basis and believe such a strategy would create value.</p>



<p class="wp-block-paragraph">RBC has a price target of $68 on Ramsay shares.</p>



<h2 id="h-fisher-amp-paykel-healthcare-corporation-ltd-asx-fph" class="wp-block-heading">Fisher &amp; Paykel Healthcare Corporation Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-fph/">ASX: FPH</a>)</h2>



<p class="wp-block-paragraph">RBC said this company's trading update revealed a strong start to the year and an upgrade to FY27 guidance.</p>



<p class="wp-block-paragraph">The broker added:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We expect FPH's hospital revenues to continue growing in mid-to-high teens in FY27-FY29 which will enable the company to deliver double digit group revenue growth. FPH has the fastest growth profile across our coverage and we now believe FPH has the best price to earnings growth ratio across our coverage.</p>
</blockquote>



<p class="wp-block-paragraph">RBC has a price target of $52 on Fisher &amp; Paykel shares.</p>



<h2 id="h-nanosonics-ltd-asx-nan" class="wp-block-heading">Nanosonics Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nan/">ASX: NAN</a>)</h2>



<p class="wp-block-paragraph">RBC said Nanosonics had a mixed result with revenues missing expectations but earnings beating.</p>



<p class="wp-block-paragraph">The broker said the Trophon business was growing and profitable, and they believed the share price was currently too bearish.</p>



<p class="wp-block-paragraph">RBC has a price target of $3.75 on Nanosonics shares.</p>



<p class="wp-block-paragraph">The broker also has an outperform rating on <strong>Integral Diagnostics Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-idx/">ASX: IDX</a>) with a price target of $3.20.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/17/csl-resmed-and-more-see-which-asx-health-stocks-rbc-capital-markets-has-upgraded/">CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Santos, Ramsay Health Care, and AMP shares reach new 52-week highs: Can they keep climbing?</title>
                <link>https://www.fool.com.au/2026/09/16/santos-ramsay-health-care-and-amp-shares-reach-new-52-week-highs-can-they-keep-climbing/</link>
                                <pubDate>Wed, 16 Sep 2026 04:48:28 +0000</pubDate>
                <dc:creator><![CDATA[Samantha Menzies]]></dc:creator>
                		<category><![CDATA[ASX Share Market News]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1874199</guid>
                                    <description><![CDATA[<p>Find out whether these ASX shares are a buy, sell, or hold now.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/16/santos-ramsay-health-care-and-amp-shares-reach-new-52-week-highs-can-they-keep-climbing/">Santos, Ramsay Health Care, and AMP shares reach new 52-week highs: Can they keep climbing?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>Santos Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sto/">ASX: STO</a>), <strong>Ramsay Health Care Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>), and <strong>AMP Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-amp/">ASX: AMP</a>) shares have climbed to fresh annual highs in Wednesday trade as the <strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) swings into the green.    </p>



<p class="wp-block-paragraph">Here's what has happened, and what brokers tip next.  </p>



<h2 id="h-santos-shares" class="wp-block-heading"><strong>Santos shares</strong></h2>



<p class="wp-block-paragraph">The <a href="https://www.fool.com.au/investing-education/asx-energy-shares/">ASX energy shares</a> have climbed over 2% to $8.74 at the time of writing, in what is the highest recorded share price for Santos since January 2020. Today's increase means the shares are now 42% higher for the year to date and 14% higher than 12 months ago.</p>



<p class="wp-block-paragraph">It looks like the oil and gas major's shares are enjoying tailwinds from a climbing oil price. According to Trading Economics, crude oil is trading around US$104 per barrel on Wednesday. This is a retreat from a high of US$105 per barrel yesterday, but it still represents a 24% increase in the price of crude oil over the past month alone.  </p>



<p class="wp-block-paragraph">Prices are rising amid new drone attacks and ongoing conflict in the Middle East, which has restricted oil supply even further. </p>



<p class="wp-block-paragraph">And investment bank Goldman Sachs said recently that it thinks crude oil could rise above US$120 if production remains well below pre-conflict levels.  </p>



<p class="wp-block-paragraph">Experts are bullish that Santos shares can keep climbing higher, too. TradingView data shows that all brokers have a strong buy rating on the stock. The $8.99 average target price implies around a 3% upside at the time of writing.</p>



<h2 id="h-ramsay-health-care-shares" class="wp-block-heading"><strong>Ramsay Health Care shares</strong></h2>



<p class="wp-block-paragraph">Ramsay Health shares are also up around 2% to a multi-year high of $54.64 at the time of writing. The share price flew higher in late August off the back of a healthcare-sector-wide rebound and the company's impressive FY26 results announcement. </p>



<p class="wp-block-paragraph">Ramsay Health shares are now up around 58% for the year to date and 63% higher than 12 months ago.</p>



<p class="wp-block-paragraph">For FY26, the company reported a 22.9% increase in its underlying net profit after tax (NPAT) and a 11.8% increase in its underlying EBIT. Revenue also climbed 4.2%. Shareholders also received a <a href="https://www.fool.com.au/definitions/dividend/">dividend</a> increase, up 13.8% to 91 cents per share for the full-year FY26.</p>



<p class="wp-block-paragraph">Looking ahead, Ramsay expects to report EBIT growth and further margin improvement in FY27, with ongoing focus on cost management, activity growth, and capital discipline.&nbsp;</p>



<p class="wp-block-paragraph">The company is also moving ahead with plans to separate its 52.79% stake in <strong>Ramsay Santé</strong>, which owns hospitals across Europe.</p>



<p class="wp-block-paragraph">But it looks like the experts want to see more evidence that the company can keep growing. TradingView data shows the majority of brokers have a hold rating, with the $51.49 average target price implying a downside of around 6%.</p>



<h2 id="h-amp-shares" class="wp-block-heading"><strong>AMP shares</strong></h2>



<p class="wp-block-paragraph">AMP shares are up around 0.5% to $2.51 at the time of writing on Wednesday. This is the highest share price AMP has traded at since November 2018. The shares are also up an impressive 37% year to date and 39% higher than a year ago. </p>



<p class="wp-block-paragraph">Ongoing geopolitical tensions and concerns about Australia's <a href="https://www.fool.com.au/investing-education/inflation/">inflation</a> data weighed heavily on <a href="https://www.fool.com.au/investing-education/financial-shares/">financial shares</a> like AMP throughout the first half of the year.</p>



<p class="wp-block-paragraph">But the diversified financial services company continues to post some strong financial results. In mid-July, it announced first-half NPAT guidance of $170 to $180 million, significantly higher than the $131 million reported for the same period last year. Investors rushed to buy the shares and sent the price flying 22% higher within a week.</p>



<p class="wp-block-paragraph">Then, early last month, AMP posted its first-half FY26 results, including a 33% year-on-year increase in underlying NPAT to $174 million, an 8.2% year-on-year increase in assets under management (AUM), and a 33% increase in AMP's Platforms net cash flows.  </p>



<p class="wp-block-paragraph">Again, investors were thrilled, and the share price has continued climbing since the announcement.</p>



<p class="wp-block-paragraph">TradingView data shows that the majority of brokers have a buy rating on AMP shares. But after such a strong rally recently, the average $2.49 target price now implies a downside of around 1%.  </p>
<p>The post <a href="https://www.fool.com.au/2026/09/16/santos-ramsay-health-care-and-amp-shares-reach-new-52-week-highs-can-they-keep-climbing/">Santos, Ramsay Health Care, and AMP shares reach new 52-week highs: Can they keep climbing?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Worried about a downturn? 3 ASX shares and 3 ETFs built to weather it</title>
                <link>https://www.fool.com.au/2026/09/16/worried-about-a-downturn-3-asx-shares-and-3-etfs-built-to-weather-it/</link>
                                <pubDate>Tue, 15 Sep 2026 19:48:18 +0000</pubDate>
                <dc:creator><![CDATA[Marc Van Dinther]]></dc:creator>
                		<category><![CDATA[Investing Strategies]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1873919</guid>
                                    <description><![CDATA[<p>No explosive growth here, that's the point of defensive investing.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/16/worried-about-a-downturn-3-asx-shares-and-3-etfs-built-to-weather-it/">Worried about a downturn? 3 ASX shares and 3 ETFs built to weather it</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">The ASX share market doesn't stay calm forever, and 2026 has been a reminder of that. With stretched valuations, slowing global growth and stubborn <a href="https://www.fool.com.au/investing-education/inflation/">inflation</a> all doing the rounds, more investors are looking to add some ballast to their portfolios.</p>



<p class="wp-block-paragraph">Here are three defensive ASX shares and three ETFs worth a look.</p>



<h2 id="h-woolworths-group-ltd-asx-wow" class="wp-block-heading">Woolworths Group Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wow/">ASX: WOW</a>)</h2>



<p class="wp-block-paragraph">Supermarkets don't stop trading in a downturn — people still need to eat. Woolworths' dominant market share in the Australian supermarket landscape has long held it in good stead even during tough economic conditions. </p>



<p class="wp-block-paragraph">And the market has noticed: the ASX share is up 33% year to date. Even as households trade down to cheaper essentials, Woolworths tends to keep the lights on and the <a href="https://www.fool.com.au/definitions/dividend/">dividends</a> flowing. </p>



<h2 id="h-ramsay-health-care-ltd-asx-rhc" class="wp-block-heading">Ramsay Health Care Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>)</h2>



<p class="wp-block-paragraph">Healthcare demand doesn't switch off when the economy slows. Ramsay is one of the largest and well-established private healthcare providers, and elective surgery volumes plus global diagnostic demand tend to hold up regardless of the cycle. </p>



<p class="wp-block-paragraph">It's the kind of business people rely on whether markets are booming or busting. The ASX share is up an impressive 56% in 2026. </p>



<h2 id="h-suncorp-group-ltd-asx-sun" class="wp-block-heading">Suncorp Group Ltd (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sun/">ASX: SUN</a>)</h2>



<p class="wp-block-paragraph">Insurance is one of those products people keep paying for no matter what. Insurance demand tends to remain steady even in weaker economic conditions. </p>



<p class="wp-block-paragraph">Suncorp hasn't been a growth story over the past 12 months, down 5%, but that's rather the point. This $21 billion ASX share is there to steady the ship, not chase the rally. </p>



<h2 id="h-vanguard-australian-shares-index-etf-asx-vas" class="wp-block-heading">Vanguard Australian Shares Index ETF (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-vas/">ASX: VAS</a>)</h2>



<p class="wp-block-paragraph">For broad, low-cost exposure with a defensive tilt, the Vanguard Australian Shares Index ETF has characteristics that make it more resilient than many global indices, leaning on Australia's banks, resources and consumer staples sectors. </p>



<p class="wp-block-paragraph">It's a simple, set-and-forget way to add local stability to a ASX shares portfolio. </p>



<h2 id="h-ishares-global-consumer-staples-etf-asx-ixi" class="wp-block-heading">iShares Global Consumer Staples ETF (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-ixi/">ASX: IXI</a>)</h2>



<p class="wp-block-paragraph">If you want global exposure to businesses people buy from no matter the economic weather, this ETF is hard to beat. Its holdings include some of the most dependable companies on the planet, such as <strong>Walmart Inc </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/nasdaq-wmt/">NASDAQ: WMT</a>), and <strong>Coca-Cola</strong> <strong>Co</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/nyse-ko/">NYSE: KO</a>). </p>



<p class="wp-block-paragraph">These are businesses with strong brands, pricing power, and customer loyalty, making their earnings far more stable than companies tied to discretionary spending. </p>



<h2 id="h-betashares-global-cash-flow-kings-etf-asx-cflo" class="wp-block-heading">Betashares Global Cash Flow Kings ETF (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-cflo/">ASX: CFLO</a>)</h2>



<p class="wp-block-paragraph">Cash is king in a downturn, and this fund is built around exactly that idea. It focuses on stocks with exceptional cash generation, holding global giants like <strong>Alphabet Inc</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/nasdaq-goog/">NASDAQ: GOOG</a>) and <strong>Visa Inc</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/nyse-v/">NYSE: V</a>).</p>



<p class="wp-block-paragraph">Two companies with the balance sheet strength to self-fund growth without leaning on debt when conditions get tough. </p>



<h2 id="h-foolish-takeaway" class="wp-block-heading">Foolish takeaway</h2>



<p class="wp-block-paragraph">None of these picks will make headlines for explosive growth, and that's the whole point of defensive investing. </p>



<p class="wp-block-paragraph">Pairing a couple of resilient ASX shares with a broad ETF or two can help smooth out the ride without forcing you to sit entirely on the sidelines. </p>



<p class="wp-block-paragraph">As always, defensive doesn't mean risk-free. It means being better positioned to weather the storm.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/16/worried-about-a-downturn-3-asx-shares-and-3-etfs-built-to-weather-it/">Worried about a downturn? 3 ASX shares and 3 ETFs built to weather it</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Up 57% this year. Guess which ASX 200 stock just hit a multi-year high?</title>
                <link>https://www.fool.com.au/2026/09/10/up-57-this-year-guess-which-asx-200-stock-just-hit-a-multi-year-high/</link>
                                <pubDate>Thu, 10 Sep 2026 03:03:15 +0000</pubDate>
                <dc:creator><![CDATA[Aaron Teboneras]]></dc:creator>
                		<category><![CDATA[Opinions]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1872512</guid>
                                    <description><![CDATA[<p>A huge turnaround has pushed this ASX healthcare stock to fresh highs.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/10/up-57-this-year-guess-which-asx-200-stock-just-hit-a-multi-year-high/">Up 57% this year. Guess which ASX 200 stock just hit a multi-year high?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">At the start of 2026,&nbsp;<strong>Ramsay Health Care Ltd</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) was hardly the kind of stock investors were chasing.</p>



<p class="wp-block-paragraph">Fast-forward 8 months, and the picture looks very different. </p>



<p class="wp-block-paragraph">Ramsay shares are up another 1.52% to $54.11 on Thursday, taking the private hospital operator to its highest level in several years.</p>



<p class="wp-block-paragraph">The stock has now surged around 57% in 2026 and sits almost 80% above its 52-week low of $30.39. </p>



<p class="wp-block-paragraph">It was changing hands at just $44.02 on 26 August. Since then, the share price has jumped almost 23% in a little over 2 weeks. </p>



<p class="wp-block-paragraph">After years of going nowhere, Ramsay has suddenly become one of the more interesting turnaround stories on the ASX.</p>



<p class="wp-block-paragraph">And I think its latest results explain a lot of the recent excitement. </p>



<h2 id="h-the-numbers-are-finally-improving" class="wp-block-heading"><strong>The numbers are finally improving</strong></h2>



<p class="wp-block-paragraph">Ramsay's&nbsp;<a href="https://www.fool.com.au/tickers/asx-rhc/announcements/2026-08-27/2a1692440/financial-results-for-the-year-ended-30-june-2026/">FY26 result</a>&nbsp;was a pretty decent one. </p>



<p class="wp-block-paragraph">Revenue came in at $18.6 billion, while underlying EBIT rose 11.8% to around $1.16 billion. </p>



<p class="wp-block-paragraph">Underlying&nbsp;<a href="https://www.fool.com.au/definitions/npat/">net profit after tax (NPAT)</a>&nbsp;increased 19.3% to $364.1 million, or 22.9% on a constant currency basis. </p>



<p class="wp-block-paragraph">Australia did much of the work, helped by higher hospital activity, better theatre utilisation, improved private health insurance pricing, and tighter cost control. </p>



<p class="wp-block-paragraph">The group's underlying EBIT margin also improved by 30 basis points to 6.2%.</p>



<p class="wp-block-paragraph">Shareholders got a little extra too, with the full-year&nbsp;<a href="https://www.fool.com.au/definitions/dividend/">dividend</a>&nbsp;rising 13.8% to 91 cents per share.</p>



<h2 id="h-the-business-could-look-very-different" class="wp-block-heading"><strong>The business could look very different</strong></h2>



<p class="wp-block-paragraph">Ramsay is moving ahead with plans to separate its 52.79% stake in <strong>Ramsay Santé</strong>, which owns hospitals across Europe.</p>



<p class="wp-block-paragraph">Shareholders are expected to vote on the proposed demerger in November.</p>



<p class="wp-block-paragraph">If the deal goes ahead, investors would be left with a simpler Ramsay business and a much clearer view of how its Australian hospitals are performing. </p>



<p class="wp-block-paragraph">Ramsay is still putting money into Australia too, with the company agreeing to buy National Capital Private Hospital in Canberra for $251 million.</p>



<p class="wp-block-paragraph">Management expects the acquisition to add to earnings in its first 12 months.</p>



<h2 id="h-would-i-buy-ramsay-shares" class="wp-block-heading"><strong>Would I buy Ramsay shares?</strong></h2>



<p class="wp-block-paragraph">This is probably where I would be a little more careful.</p>



<p class="wp-block-paragraph">At $54.11, Ramsay shares have already moved above the average TipRanks analyst price target of $50.66. The highest target is $55.69. </p>



<p class="wp-block-paragraph">Director Michael Siddle also&nbsp;<a href="https://www.fool.com.au/tickers/asx-rhc/announcements/2026-08-28/2a1693139/change-of-directors-interest-notice-m-siddle/">sold 1 million shares</a>&nbsp;at $49 shortly after the result, in an off-market transaction worth $49 million.</p>



<p class="wp-block-paragraph">Yes, I still like what I am seeing from the business, and I think the turnaround has more substance behind it. </p>



<p class="wp-block-paragraph">But I wouldn't be chasing Ramsay shares purely because they have been going up.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/10/up-57-this-year-guess-which-asx-200-stock-just-hit-a-multi-year-high/">Up 57% this year. Guess which ASX 200 stock just hit a multi-year high?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>CSL led the ASX healthcare shares rebound. Can it continue?</title>
                <link>https://www.fool.com.au/2026/09/08/csl-led-the-asx-healthcare-shares-rebound-can-it-continue/</link>
                                <pubDate>Mon, 07 Sep 2026 20:30:00 +0000</pubDate>
                <dc:creator><![CDATA[Marc Van Dinther]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1871278</guid>
                                    <description><![CDATA[<p>The rebound of healthcare stocks looks promising, but proving the recovery is real remains.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/08/csl-led-the-asx-healthcare-shares-rebound-can-it-continue/">CSL led the ASX healthcare shares rebound. Can it continue?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">For years, ASX healthcare shares have been the market's rotten apple. Once viewed as a defensive safe haven, the sector became one of the ASX's biggest laggards.</p>



<p class="wp-block-paragraph">The <strong>S&amp;P/ASX 200 Health Care Index </strong>(ASX: XHJ) is still down 33% over five years and 18% over the past 12 months. Between January 2025 and June 2026, the index lost more than half its value.</p>



<p class="wp-block-paragraph">Then August happened. The ASX 200 Health Care index surged 13% over a month and now sits 44% above its June low, comfortably beating the <strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO), which gained 3% over the same period.</p>



<p class="wp-block-paragraph">So, have ASX <a href="https://www.fool.com.au/investing-education/healthcare-shares/">healthcare shares </a>finally turned the corner?</p>



<h2 id="h-csl-leads-the-charge" class="wp-block-heading">CSL leads the charge</h2>



<p class="wp-block-paragraph">The sector entered August with expectations firmly beaten down. That proved to be a blessing.</p>



<p class="wp-block-paragraph">Companies largely cleared the low bar, with cost control doing much of the heavy lifting. Healthcare was also the only sector where more companies upgraded their outlooks for the year ahead than downgraded them.</p>



<p class="wp-block-paragraph"><strong>CSL Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-csl/">ASX: CSL</a>) was the standout. Its shares jumped 40% in August after plasma product sales for the June half came in ahead of expectations. </p>



<p class="wp-block-paragraph">More importantly, management pointed to improving gross margins at CSL Behring, the plasma business that has caused plenty of headaches in recent years. UBS now believes the worst could be behind CSL ahead of its CEO transition in 2027.</p>



<p class="wp-block-paragraph">Other healthcare heavyweights also delivered. <strong>Ansell Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-ann/">ASX: ANN</a>) jumped 23% after beating expectations, with its FY27 <a href="https://www.fool.com.au/definitions/company-guidance/">guidance </a>implying double-digit earnings-per-share growth at the midpoint. </p>



<p class="wp-block-paragraph"><strong>Ramsay Health Care Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) gained 16% after a better-than-expected FY26 result. Its new management team expects further margin expansion in FY27, helped by more predictable private health insurance agreements, better operating theatre utilisation and procurement savings.</p>



<p class="wp-block-paragraph">The rally wasn't limited to those three names. Eight of the sector's 10 largest ASX healthcare shares finished August higher. <strong>Cochlear Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-coh/">ASX: COH</a>) climbed 13%, <strong>Telix Pharmaceuticals Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-tlx/">ASX: TLX</a>) rose 10%, and <strong>ResMed Inc </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rmd/">ASX: RMD</a>) gained close to 10%.</p>



<h2 id="h-can-the-rebound-continue" class="wp-block-heading">Can the rebound continue?</h2>



<p class="wp-block-paragraph">This is where things get interesting. August was impressive, but FY27 will be the real test.</p>



<p class="wp-block-paragraph">Management teams are generally optimistic, yet analysts aren't quite as convinced. According to a recent Macquarie note, consensus FY27 earnings forecasts for the sector were actually cut by more than 2% during August.</p>



<p class="wp-block-paragraph">There's another problem: valuations have rebounded alongside share prices. The bargain-basement appeal that existed at June's lows has largely disappeared. Investors are now paying more for the turnaround they hope is coming.</p>



<p class="wp-block-paragraph">The August reporting season suggests CSL and several of its peers may finally be back on firmer ground. But after such a powerful rebound, the easy part may already be over.</p>



<p class="wp-block-paragraph">Now, ASX healthcare shares need to deliver. </p>



<p class="wp-block-paragraph" id="h-csl-led-the-asx-healthcare-shares-rebound-can-it-continue"></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.fool.com.au/2026/09/08/csl-led-the-asx-healthcare-shares-rebound-can-it-continue/">CSL led the ASX healthcare shares rebound. Can it continue?</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Top 3 ASX healthcare shares to buy after a brutal year</title>
                <link>https://www.fool.com.au/2026/09/05/top-3-asx-healthcare-shares-to-buy-after-a-brutal-year/</link>
                                <pubDate>Fri, 04 Sep 2026 23:30:00 +0000</pubDate>
                <dc:creator><![CDATA[Mark Verhoeven]]></dc:creator>
                		<category><![CDATA[Healthcare Shares]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1870578</guid>
                                    <description><![CDATA[<p>Three very different ways to back healthcare.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/05/top-3-asx-healthcare-shares-to-buy-after-a-brutal-year/">Top 3 ASX healthcare shares to buy after a brutal year</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">ASX healthcare shares have spent the past year being repriced harder than almost any other corner of the market.</p>



<p class="wp-block-paragraph"><strong>CSL Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-csl/">ASX: CSL</a>) fell as low as $90 before staging a recovery, and <strong>Pro Medicus Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-pme/">ASX: PME</a>) has roughly halved from the high it set less than a year ago.</p>



<p class="wp-block-paragraph">Yet the sector <a href="https://www.fool.com.au/2026/08/23/asx-200-healthcare-shares-soar-9-amid-notable-fy26-reports-from-csl-pro-medicus-week-34-2026/">rose</a> 9% in a week during reporting season, which tells you sentiment may have started to turn.</p>



<h2 id="h-why-asx-healthcare-shares-fell-so-far" class="wp-block-heading">Why ASX healthcare shares fell so far</h2>



<p class="wp-block-paragraph">The damage was mostly self-inflicted at the company level.</p>



<p class="wp-block-paragraph">CSL wrote down its Vifor acquisition, Pro Medicus derated from an extraordinary multiple, and drug pricing pressure from the United States hung over the entire sector.</p>



<p class="wp-block-paragraph">None of those problems has vanished, but the price investors are now asked to pay for them has changed.</p>



<p class="wp-block-paragraph">That is usually where the better opportunities in a beaten-up sector are found.</p>



<h2 id="h-1-csl" class="wp-block-heading">1. CSL</h2>



<p class="wp-block-paragraph">CSL trades around $175 against a 52-week range of $90.00 to $222.47.</p>



<p class="wp-block-paragraph">FY26 was openly badged as a reset year.</p>



<p class="wp-block-paragraph">Revenue <a href="https://www.fool.com.au/2026/08/18/csl-earnings-fy26-sees-reset-and-path-to-future-growth/">slipped</a> 1% to US$15.8 billion, and impairments of US$7.1 billion drove a statutory loss of US$2.6 billion.</p>



<p class="wp-block-paragraph">Underlying profit after tax and amortisation still reached US$3.1 billion, which is the figure worth focusing on because the impairments were non-cash and largely historical.</p>



<p class="wp-block-paragraph">The forward numbers are what matter here.</p>



<p class="wp-block-paragraph">CSL is targeting US$400 million of annual cost savings, rising to US$550 million by FY28.</p>



<p class="wp-block-paragraph">FY27 guidance points to underlying profit growth of around 5%, with a further A$1.1 billion buyback authorised.</p>



<p class="wp-block-paragraph">On the flipside, the company's dividend was held at US$2.92 per share and net debt sits at 1.8 times EBITDA.</p>



<h2 id="h-2-pro-medicus" class="wp-block-heading">2. Pro Medicus</h2>



<p class="wp-block-paragraph">Pro Medicus is the quality name and remains the expensive one.</p>



<p class="wp-block-paragraph">The shares trade near $185 against a 52-week high of $321.57, so the derating has been severe.</p>



<p class="wp-block-paragraph">FY26 revenue rose 22.9% to $261.7 million and underlying net profit climbed 24.1% to $144.7 million.</p>



<p class="wp-block-paragraph">The company's underlying EBIT margin reached 74.9% and the company remains debt-free with $252.3 million in cash.</p>



<p class="wp-block-paragraph">Chief executive Dr Sam Hupert was optimistic about the previous year:</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph">We were aiming for 30% increases in EBIT and NPAT, and we exceeded both on a constant currency basis.</p>
</blockquote>



<p class="wp-block-paragraph">The company signed $407 million of new <a href="https://www.promed.com.au/pro-medicus-limited-full-year-results-10/">contracts</a> and lifted its dividend 25.5% to 69 cents.</p>



<p class="wp-block-paragraph">At roughly 75 times earnings the shares are still priced for something close to perfection, though considerably less so than they were twelve months ago.</p>



<h2 id="h-3-ramsay-health-care" class="wp-block-heading">3. Ramsay Health Care</h2>



<p class="wp-block-paragraph"><strong>Ramsay Health Care Ltd </strong>(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) is the turnaround story of the three.</p>



<p class="wp-block-paragraph">FY26 revenue reached $18.6 billion and underlying EBIT rose 11.8% to $1.2 billion.</p>



<p class="wp-block-paragraph">The EBIT margin improved 30 basis points to 6.2%, which is the number the market had been waiting on.</p>



<p class="wp-block-paragraph">The full-year dividend lifted 13.8% to 91 cents.</p>



<p class="wp-block-paragraph">The bigger catalyst is linked to its markets.</p>



<p class="wp-block-paragraph">Ramsay plans to separate Ramsay Santé, its European business, with a shareholder vote scheduled for 24 November.</p>



<p class="wp-block-paragraph">Approval would leave behind a simpler, Australian-focused hospital operator with a cleaner balance sheet and a far easier story for investors to value.</p>



<h2 id="h-what-could-go-wrong-with-asx-healthcare-shares" class="wp-block-heading">What could go wrong with ASX healthcare shares</h2>



<p class="wp-block-paragraph">Each of these stocks carry their own risk.</p>



<p class="wp-block-paragraph">CSL still has to prove that its cost programme can deliver, and its Vifor division is guided to shrink around 25% in FY27.</p>



<p class="wp-block-paragraph">Pro Medicus depends on continued contract wins in a US market where it already holds meaningful share.</p>



<p class="wp-block-paragraph">Then on the other hand, Ramsay's separation still requires a shareholder vote in November, and demergers routinely take longer and cost more than the initial timetable suggests.</p>



<h2 id="h-foolish-takeaway" class="wp-block-heading">Foolish takeaway</h2>



<p class="wp-block-paragraph">Of these three ASX healthcare shares, CSL offers the clearest difference between price and normalised earnings.</p>



<p class="wp-block-paragraph">Pro Medicus has the best business and the hardest valuation to defend, whereas Ramsay has the most tangible catalyst and yet the least growth behind it.</p>



<p class="wp-block-paragraph">A brutal twelve months has left the sector significant cheaper than it was, without making any of these three businesses straightforward to own.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/05/top-3-asx-healthcare-shares-to-buy-after-a-brutal-year/">Top 3 ASX healthcare shares to buy after a brutal year</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                            <item>
                                <title>Own BHP, Woodside or Coles shares? Here&#039;s what investors should know</title>
                <link>https://www.fool.com.au/2026/09/03/own-bhp-woodside-or-coles-shares-heres-what-investors-should-know/</link>
                                <pubDate>Thu, 03 Sep 2026 01:50:43 +0000</pubDate>
                <dc:creator><![CDATA[Aaron Teboneras]]></dc:creator>
                		<category><![CDATA[Dividend Investing]]></category>

                <guid isPermaLink="false">https://www.fool.com.au/?p=1870164</guid>
                                    <description><![CDATA[<p>Some big-name shares could distort the market today.</p>
<p>The post <a href="https://www.fool.com.au/2026/09/03/own-bhp-woodside-or-coles-shares-heres-what-investors-should-know/">Own BHP, Woodside or Coles shares? Here&#039;s what investors should know</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></description>
                                                                                            <content:encoded><![CDATA[
<p class="wp-block-paragraph">A busy day is set to be underway on the stock market, with several well-known <strong>S&amp;P/ASX 200 Index</strong> (ASX: XJO) companies trading <a href="https://www.fool.com.au/definitions/ex-dividend/">ex-dividend</a> today. </p>



<p class="wp-block-paragraph">The list includes <strong>BHP Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-bhp/">ASX: BHP</a>), <strong>Woodside Energy Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-wds/">ASX: WDS</a>), and <strong>Coles Group Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-col/">ASX: COL</a>), along with four other ASX 200 shares.</p>



<p class="wp-block-paragraph">Combined, the <a href="https://www.fool.com.au/definitions/dividend/">dividends</a> are worth around 31 points on the ASX 200, according to <a href="https://www.ig.com/au" target="_blank" rel="noreferrer noopener">IG</a>. </p>



<p class="wp-block-paragraph">That could make some of the share price moves look worse than they really are on Thursday.</p>



<p class="wp-block-paragraph">Let's take a closer look.</p>



<h2 id="h-bhp-woodside-and-coles-lead-the-way" class="wp-block-heading"><strong>BHP, Woodside, and Coles lead the way</strong></h2>



<p class="wp-block-paragraph">BHP is easily the largest company on today's list.</p>



<p class="wp-block-paragraph">The mining giant closed Wednesday at $64.65 and is trading ex-dividend for $1.39 per share,&nbsp;<a href="https://www.fool.com.au/definitions/franking-credits/">fully franked</a>.</p>



<p class="wp-block-paragraph">That means anyone buying BHP shares from today will not receive the payment, which is due to eligible shareholders on 23 September.</p>



<p class="wp-block-paragraph">Woodside is another heavyweight going ex-dividend. </p>



<p class="wp-block-paragraph">Its shares finished yesterday at $33.08 and are now trading without a 79.51-cent fully-franked dividend attached. Woodside is due to pay shareholders on 25 September. </p>



<p class="wp-block-paragraph">Coles closed Wednesday at $23.89 and has a 37-cent fully-franked dividend coming off its share price today. The supermarket giant will make the payment on 22 September.</p>



<p class="wp-block-paragraph">However, with all three carrying such huge index weightings, going ex-dividend is likely to put some pressure on the ASX 200 today.</p>



<h2 id="h-4-more-asx-200-shares-to-watch" class="wp-block-heading"><strong>4 more ASX 200 shares to watch</strong></h2>



<p class="wp-block-paragraph">There are also several other payouts investors should be aware of.</p>



<p class="wp-block-paragraph"><strong>Amcor Plc</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-amc/">ASX: AMC</a>) closed at $64.15 and is trading ex-dividend for 92 cents per share. Unlike the other larger payouts today, the Amcor dividend is unfranked.</p>



<p class="wp-block-paragraph"><strong>Ramsay Health Care Ltd</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-rhc/">ASX: RHC</a>) finished Wednesday at $52.38 and is going ex-dividend for 48.5 cents per share, fully franked.</p>



<p class="wp-block-paragraph">Meanwhile, <strong>NIB Holdings Ltd</strong> (<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-nhf/">ASX: NHF</a>) closed at $6.97 and is trading without its 21-cent fully-franked dividend.</p>



<p class="wp-block-paragraph">Rounding out the group is&nbsp;<strong>Sigma Healthcare Ltd</strong>&nbsp;(<a class="tickerized-link" href="https://www.fool.com.au/tickers/asx-sig/">ASX: SIG</a>), which closed at $2.71. Its latest dividend is 2 cents per share, also fully franked.</p>



<p class="wp-block-paragraph">Sigma shareholders are due to receive their payment on 22 September, Ramsay on 24 September, and NIB on 7 October.</p>



<h2 id="h-what-investors-should-keep-in-mind" class="wp-block-heading"><strong>What investors should keep in mind</strong></h2>



<p class="wp-block-paragraph">There is a fair bit going on with the index today, so the headline move may not tell the full story.</p>



<p class="wp-block-paragraph">BHP, Woodside, and Coles are all large enough to have an impact, and having all 3 go ex-dividend on the same day adds some extra weight.</p>



<p class="wp-block-paragraph">So, if the ASX 200 looks a bit weak, the dividend effect is worth factoring in. </p>
<p>The post <a href="https://www.fool.com.au/2026/09/03/own-bhp-woodside-or-coles-shares-heres-what-investors-should-know/">Own BHP, Woodside or Coles shares? Here&#039;s what investors should know</a> appeared first on <a href="https://www.fool.com.au">The Motley Fool Australia</a>.</p>
]]></content:encoded>
                                                                                                                    </item>
                    </channel>
</rss>
